{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:16:56Z","timestamp":1783073816890,"version":"3.54.6"},"reference-count":257,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Individual authors did not receive funding specifically for this manuscript, but the manuscript editing was funded by Pharvaris"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-026-09178-y","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:29:57Z","timestamp":1783070997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Targeting of the Bradykinin B2 Receptor in Immunological and Vascular Diseases: Insights from Kinin Biology to Clinical Outcomes"],"prefix":"10.1007","volume":"69","author":[{"given":"Marc A.","family":"Riedl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny M.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Magerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Ayg\u00f6ren-P\u00fcrs\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin H.","family":"Schmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Pardali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lesage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Newby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"9178_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1152\/ajplegacy.1949.156.2.261","volume":"156","author":"M Rocha e Silva","year":"1949","unstructured":"Rocha e Silva M, Beraldo WT, Rosenfeld G (1949) Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Physiol 156:261\u2013273. https:\/\/doi.org\/10.1152\/ajplegacy.1949.156.2.261","journal-title":"Am J Physiol"},{"key":"9178_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2017.04.001","author":"AP Kaplan","year":"2017","unstructured":"Kaplan AP, Joseph K (2017) Pathogenesis of hereditary angioedema: The role of the bradykinin-forming cascade. Immunol Allergy Clin North Am 37:513\u2013525. https:\/\/doi.org\/10.1016\/j.iac.2017.04.001","journal-title":"Immunol Allergy Clin North Am"},{"key":"9178_CR3","doi-asserted-by":"publisher","first-page":"e12673","DOI":"10.1002\/rth2.12673","volume":"6","author":"AS Pinheiro","year":"2022","unstructured":"Pinheiro AS, Silbak S, Schmaier AH (2022) Bradykinin - An elusive peptide in measuring and understanding. Res Pract Thromb Haemost 6:e12673. https:\/\/doi.org\/10.1002\/rth2.12673","journal-title":"Res Pract Thromb Haemost"},{"key":"9178_CR4","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1111\/j.1538-7836.2007.02770.x","volume":"5","author":"AH Schmaier","year":"2007","unstructured":"Schmaier AH, McCrae KR (2007) The plasma kallikrein-kinin system: its evolution from contact activation. J Thromb Haemost 5:2323\u20132329. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02770.x","journal-title":"J Thromb Haemost"},{"key":"9178_CR5","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1517\/17460441.2012.729038","volume":"7","author":"ET Whalley","year":"2012","unstructured":"Whalley ET, Figueroa CD, Gera L, Bhoola KD (2012) Discovery and therapeutic potential of kinin receptor antagonists. Expert Opin Drug Discov 7:1129\u20131148. https:\/\/doi.org\/10.1517\/17460441.2012.729038","journal-title":"Expert Opin Drug Discov"},{"key":"9178_CR6","doi-asserted-by":"publisher","first-page":"106305","DOI":"10.1016\/j.intimp.2020.106305","volume":"82","author":"F Marceau","year":"2020","unstructured":"Marceau F, Bachelard H, Bouthillier J, Fortin JP, Morissette G, Bawolak MT et al (2020) Bradykinin receptors: Agonists, antagonists, expression, signaling, and adaptation to sustained stimulation. Int Immunopharmacol 82:106305. https:\/\/doi.org\/10.1016\/j.intimp.2020.106305","journal-title":"Int Immunopharmacol"},{"key":"9178_CR7","doi-asserted-by":"publisher","first-page":"171466","DOI":"10.1016\/j.peptides.2026.171466","volume":"195","author":"A Sahli","year":"2026","unstructured":"Sahli A, R CG, Marceau F (2026) Non-peptide bradykinin B2 receptor ligands possessing the substituted quinolinyl moiety: Pharmacological properties and prospective clinical uses. Peptides 195:171466. https:\/\/doi.org\/10.1016\/j.peptides.2026.171466","journal-title":"Peptides"},{"key":"9178_CR8","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.3892\/or.2019.7380","volume":"42","author":"W Wang","year":"2019","unstructured":"Wang W, Zhou Y, Wei R, Jiang G, Li F, Chen X et al (2019) Bradykinin promotes proliferation, migration, and invasion of cervical cancer cells through STAT3 signaling pathways. Oncol Rep 42:2521\u20132527. https:\/\/doi.org\/10.3892\/or.2019.7380","journal-title":"Oncol Rep"},{"key":"9178_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12079-021-00652-0","volume":"16","author":"DAB Rex","year":"2022","unstructured":"Rex DAB, Deepak K, Vaid N, Dagamajalu S, Kandasamy RK, Flo TH et al (2022) A modular map of Bradykinin-mediated inflammatory signaling network. J Cell Commun Signal 16:301\u2013310. https:\/\/doi.org\/10.1007\/s12079-021-00652-0","journal-title":"J Cell Commun Signal"},{"key":"9178_CR10","doi-asserted-by":"publisher","unstructured":"Kaplan AP, Ghebrehiwet B, Joseph K (2024) Alzheimer\u2019s disease: in vitro and in vivo evidence of activation of the plasma bradykinin-forming cascade and implications for therapy. Cells 13:2039. https:\/\/doi.org\/10.3390\/cells13242039","DOI":"10.3390\/cells13242039"},{"key":"9178_CR11","doi-asserted-by":"crossref","unstructured":"Scharfstein J (2025) Chapter 17 - Bradykinin receptors in neglected parasitic and viral diseases. In: Couture R (ed) Bradykinin. Academic Press, pp 413\u2013\u2009477","DOI":"10.1016\/B978-0-443-28907-1.00014-1"},{"key":"9178_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/978-1-4615-9546-5_49","volume":"247B","author":"A Barlas","year":"1989","unstructured":"Barlas A, Gao X, Greenbaum LM (1989) Identification of thiol-activated T-kininogenases in the rat and mouse submandibular glands. Adv Exp Med Biol 247B:293\u2013295. https:\/\/doi.org\/10.1007\/978-1-4615-9546-5_49","journal-title":"Adv Exp Med Biol"},{"key":"9178_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/0304-4165(86)90216-3","volume":"884","author":"W Sakamoto","year":"1986","unstructured":"Sakamoto W, Yoshikawa K, Yokoyama A, Kohri M (1986) T-kinin is released from T-kininogen by consecutive cleavage by cathepsin E-like proteinase and 72\u00a0kDa proteinase. Biochim Biophys Acta 884:607\u2013609. https:\/\/doi.org\/10.1016\/0304-4165(86)90216-3","journal-title":"Biochim Biophys Acta"},{"key":"9178_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-1-4615-9546-5_17","volume":"247B","author":"W Sakamoto","year":"1989","unstructured":"Sakamoto W, Satoh F, Nagasawa S, Handa H, Suzuki S, Uehara S et al (1989) A novel kinin, Met-Ile-Ser-bradykinin (Met-T-kinin) is released from T-kininogen by an acid proteinase of granulomatous tissues in rats. Adv Exp Med Biol 247B:103\u2013108. https:\/\/doi.org\/10.1007\/978-1-4615-9546-5_17","journal-title":"Adv Exp Med Biol"},{"key":"9178_CR15","doi-asserted-by":"publisher","first-page":"8601","DOI":"10.1016\/S0021-9258(17)39515-7","volume":"260","author":"Y Takagaki","year":"1985","unstructured":"Takagaki Y, Kitamura N, Nakanishi S (1985) Cloning and sequence analysis of cDNAs for human high molecular weight and low molecular weight prekininogens. Primary structures of two human prekininogens. J Biol Chem 260:8601\u20138609","journal-title":"J Biol Chem"},{"key":"9178_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0031-6997(25)00058-4","volume":"44","author":"KD Bhoola","year":"1992","unstructured":"Bhoola KD, Figueroa CD, Worthy K (1992) Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44:1\u201380","journal-title":"Pharmacol Rev"},{"key":"9178_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1515\/BC.2004.025","volume":"385","author":"CC Cardoso","year":"2004","unstructured":"Cardoso CC, Garrett T, Cayla C, Meneton P, Pesquero JB, Bader M (2004) Structure and expression of two kininogen genes in mice. Biol Chem 385:295\u2013301. https:\/\/doi.org\/10.1515\/BC.2004.025","journal-title":"Biol Chem"},{"key":"9178_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1152\/physiolgenomics.00244.2005","volume":"26","author":"EG Shesely","year":"2006","unstructured":"Shesely EG, Hu CB, Alhenc-Gelas F, Meneton P, Carretero OA (2006) A second expressed kininogen gene in mice. Physiol Genomics 26:152\u2013157. https:\/\/doi.org\/10.1152\/physiolgenomics.00244.2005","journal-title":"Physiol Genomics"},{"issue":"Suppl 7","key":"9178_CR19","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/00005344-198706107-00008","volume":"10","author":"N Kitamura","year":"1987","unstructured":"Kitamura N, Ohkubo H, Nakanishi S (1987) Molecular biology of the angiotensinogen and kininogen genes. J Cardiovasc Pharmacol 10(Suppl 7):S49\u201353. https:\/\/doi.org\/10.1097\/00005344-198706107-00008","journal-title":"J Cardiovasc Pharmacol"},{"key":"9178_CR20","first-page":"215","volume":"36","author":"LM Greenbaum","year":"1992","unstructured":"Greenbaum LM (1992) The T-kininogen, T-kinin system of the rat. Agents Actions Suppl 36:215\u2013222","journal-title":"Agents Actions Suppl"},{"key":"9178_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2007.10.007","author":"L Zhou","year":"2008","unstructured":"Zhou L, Li-Ling J, Huang H, Ma F, Li Q (2008) Phylogenetic analysis of vertebrate kininogen genes. Genomics 91:129\u2013141. https:\/\/doi.org\/10.1016\/j.ygeno.2007.10.007","journal-title":"Genomics"},{"key":"9178_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1590\/s0100-879x2000000600008","volume":"33","author":"DJ Campbell","year":"2000","unstructured":"Campbell DJ (2000) Towards understanding the kallikrein-kinin system: insights from measurement of kinin peptides. Braz J Med Biol Res 33:665\u2013677. https:\/\/doi.org\/10.1590\/s0100-879x2000000600008","journal-title":"Braz J Med Biol Res"},{"key":"9178_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaci.2009.02.006","volume":"124","author":"K Joseph","year":"2009","unstructured":"Joseph K, Tholanikunnel BG, Kaplan AP (2009) Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor. J Allergy Clin Immunol 124:143\u2013149. https:\/\/doi.org\/10.1016\/j.jaci.2009.02.006","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/BF02737655","volume":"16","author":"HS Margolius","year":"1998","unstructured":"Margolius HS (1998) Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Clin Rev Allergy Immunol 16:337\u2013349. https:\/\/doi.org\/10.1007\/BF02737655","journal-title":"Clin Rev Allergy Immunol"},{"key":"9178_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/BF02737659","volume":"16","author":"AP Kaplan","year":"1998","unstructured":"Kaplan AP, Joseph K, Shibayama Y, Nakazawa Y, Ghebrehiwet B, Reddigari S et al (1998) Bradykinin formation. Plasma and tissue pathways and cellular interactions. Clin Rev Allergy Immunol 16:403\u2013429. https:\/\/doi.org\/10.1007\/BF02737659","journal-title":"Clin Rev Allergy Immunol"},{"key":"9178_CR26","doi-asserted-by":"publisher","first-page":"25873","DOI":"10.1016\/S0021-9258(18)35690-4","volume":"267","author":"GX Zhou","year":"1992","unstructured":"Zhou GX, Chao L, Chao J (1992) Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem 267:25873\u201325880","journal-title":"J Biol Chem"},{"key":"9178_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1515\/bchm2.1981.362.1.317","volume":"362","author":"R Geiger","year":"1981","unstructured":"Geiger R, Stuckstedte U, Clausnitzer B, Fritz H (1981) Progressive inhibition of human glandular (urinary) kallikrein by human serum and identification of the progressive antikallikrein as alpha 1-antitrypsin (alpha 1-protease inhibitor). Hoppe Seylers Z Physiol Chem 362:317\u2013325. https:\/\/doi.org\/10.1515\/bchm2.1981.362.1.317","journal-title":"Hoppe Seylers Z Physiol Chem"},{"key":"9178_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jtha.2023.09.027","volume":"22","author":"BM Mohammed","year":"2024","unstructured":"Mohammed BM, Sun MF, Cheng Q, Litvak M, McCrae KR, Emsley J et al (2024) High molecular weight kininogen interactions with the homologs prekallikrein and factor XI: importance to surface-induced coagulation. J Thromb Haemost 22:225\u2013237. https:\/\/doi.org\/10.1016\/j.jtha.2023.09.027","journal-title":"J Thromb Haemost"},{"key":"9178_CR29","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1182\/blood.2020004818","volume":"136","author":"BG Kaira","year":"2020","unstructured":"Kaira BG, Slater A, McCrae KR, Dreveny I, Sumya U, Mutch NJ et al (2020) Factor XII and kininogen asymmetric assembly with gC1qR\/C1QBP\/P32 is governed by allostery. Blood 136:1685\u20131697. https:\/\/doi.org\/10.1182\/blood.2020004818","journal-title":"Blood"},{"key":"9178_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1067\/mai.2002.121316","volume":"109","author":"AP Kaplan","year":"2002","unstructured":"Kaplan AP, Joseph K, Silverberg M (2002) Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 109:195\u2013209. https:\/\/doi.org\/10.1067\/mai.2002.121316","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1515\/BC.2001.012","volume":"382","author":"K Joseph","year":"2001","unstructured":"Joseph K, Ghebrehiwet B, Kaplan AP (2001) Activation of the kinin-forming cascade on the surface of endothelial cells. Biol Chem 382:71\u201375. https:\/\/doi.org\/10.1515\/BC.2001.012","journal-title":"Biol Chem"},{"key":"9178_CR32","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1172\/JCI119669","volume":"100","author":"RW Colman","year":"1997","unstructured":"Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A et al (1997) Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 100:1481\u20131487. https:\/\/doi.org\/10.1172\/JCI119669","journal-title":"J Clin Invest"},{"key":"9178_CR33","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1073\/pnas.95.7.3615","volume":"95","author":"AA Hasan","year":"1998","unstructured":"Hasan AA, Zisman T, Schmaier AH (1998) Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci U S A 95:3615\u20133620. https:\/\/doi.org\/10.1073\/pnas.95.7.3615","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9178_CR34","doi-asserted-by":"publisher","first-page":"13040","DOI":"10.1074\/jbc.271.22.13040","volume":"271","author":"H Herwald","year":"1996","unstructured":"Herwald H, Dedio J, Kellner R, Loos M, Muller-Esterl W (1996) Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J Biol Chem 271:13040\u201313047. https:\/\/doi.org\/10.1074\/jbc.271.22.13040","journal-title":"J Biol Chem"},{"key":"9178_CR35","doi-asserted-by":"publisher","first-page":"8552","DOI":"10.1073\/pnas.93.16.8552","volume":"93","author":"K Joseph","year":"1996","unstructured":"Joseph K, Ghebrehiwet B, Peerschke EI, Reid KB, Kaplan AP (1996) Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular heads of C1q (gC1q-R). Proc Natl Acad Sci U S A 93:8552\u20138557. https:\/\/doi.org\/10.1073\/pnas.93.16.8552","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9178_CR36","doi-asserted-by":"publisher","unstructured":"Merkulova AA, Abdalian S, Silbak S, Pinheiro A, Schmaier AH (2023) C1 inhibitor and prolylcarboxypeptidase modulate prekallikrein activation on endothelial cells. J Allergy Clin Immunol 152:961\u2009\u2013\u2009971.e7. https:\/\/doi.org\/10.1016\/j.jaci.2023.06.017","DOI":"10.1016\/j.jaci.2023.06.017"},{"key":"9178_CR37","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood.V91.2.516","volume":"91","author":"G Motta","year":"1998","unstructured":"Motta G, Rojkjaer R, Hasan AA, Cines DB, Schmaier AH (1998) High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 91:516\u2013528","journal-title":"Blood"},{"key":"9178_CR38","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1084\/jem.133.4.696","volume":"133","author":"AP Kaplan","year":"1971","unstructured":"Kaplan AP, Austen KF (1971) A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 133:696\u2013712. https:\/\/doi.org\/10.1084\/jem.133.4.696","journal-title":"J Exp Med"},{"key":"9178_CR39","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1182\/blood.2021012945","volume":"139","author":"SK Dickeson","year":"2022","unstructured":"Dickeson SK, Kumar S, Sun MF, Mohammed BM, Phillips DR, Whisstock JC et al (2022) A mechanism for hereditary angioedema caused by a lysine 311-to-glutamic acid substitution in plasminogen. Blood 139:2816\u20132829. https:\/\/doi.org\/10.1182\/blood.2021012945","journal-title":"Blood"},{"key":"9178_CR40","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood-2016-03-705384","volume":"128","author":"OA Marcos-Contreras","year":"2016","unstructured":"Marcos-Contreras OA, Martinez de Lizarrondo S, Bardou I, Orset C, Pruvost M, Anfray A et al (2016) Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism. Blood 128:2423\u20132434. https:\/\/doi.org\/10.1182\/blood-2016-03-705384","journal-title":"Blood"},{"key":"9178_CR41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1182\/blood.2023022254","volume":"143","author":"SK Dickeson","year":"2024","unstructured":"Dickeson SK, Kumar S, Sun MF, Litvak M, He TZ, Phillips DR et al (2024) A mechanism for hereditary angioedema caused by a methionine-379-to-lysine substitution in kininogens. Blood 143:641\u2013650. https:\/\/doi.org\/10.1182\/blood.2023022254","journal-title":"Blood"},{"key":"9178_CR42","doi-asserted-by":"publisher","first-page":"e20036","DOI":"10.1371\/journal.pone.0020036","volume":"6","author":"J Dobo","year":"2011","unstructured":"Dobo J, Major B, Kekesi KA, Szabo I, Megyeri M, Hajela K et al (2011) Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1. PLoS One 6:e20036 https:\/\/doi.org\/10.1371\/journal.pone.0020036","journal-title":"PLoS ONE"},{"key":"9178_CR43","doi-asserted-by":"publisher","first-page":"108269","DOI":"10.1016\/j.intimp.2021.108269","volume":"101","author":"X Lu","year":"2021","unstructured":"Lu X, Liu J, Wei T, Zhou X (2021) Elevated salivary activity of mast cell chymase of periodontitis patients, and a new bradykinin generation cascade, mediating the cross-talks between mast cell and gingival fibroblast. Int Immunopharmacol 101:108269. https:\/\/doi.org\/10.1016\/j.intimp.2021.108269","journal-title":"Int Immunopharmacol"},{"key":"9178_CR44","first-page":"861","volume":"74","author":"T Imamura","year":"1996","unstructured":"Imamura T, Dubin A, Moore W, Tanaka R, Travis J (1996) Induction of vascular permeability enhancement by human tryptase: dependence on activation of prekallikrein and direct release of bradykinin from kininogens. Lab Invest 74:861\u2013870","journal-title":"Lab Invest"},{"key":"9178_CR45","doi-asserted-by":"publisher","first-page":"33224","DOI":"10.1074\/jbc.273.50.33224","volume":"273","author":"A Kozik","year":"1998","unstructured":"Kozik A, Moore RB, Potempa J, Imamura T, Rapala-Kozik M, Travis J (1998) A novel mechanism for bradykinin production at inflammatory sites. Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreins on native and oxidized kininogens. J Biol Chem 273:33224\u201333229. https:\/\/doi.org\/10.1074\/jbc.273.50.33224","journal-title":"J Biol Chem"},{"key":"9178_CR46","doi-asserted-by":"publisher","first-page":"L505","DOI":"10.1152\/ajplung.00347.2007","volume":"294","author":"LG Coffman","year":"2008","unstructured":"Coffman LG, Brown JC, Johnson DA, Parthasarathy N, D\u2019Agostino RB Jr., Lively MO et al (2008) Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol 294:L505\u2013L515. https:\/\/doi.org\/10.1152\/ajplung.00347.2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"9178_CR47","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1515\/bchm3.1988.369.2.1009","volume":"369","author":"F Sato","year":"1988","unstructured":"Sato F, Nagasawa S (1988) Mechanism of kinin release from human low-molecular-mass-kininogen by the synergistic action of human plasma kallikrein and leukocyte elastase. Biol Chem Hoppe Seyler 369:1009\u20131017. https:\/\/doi.org\/10.1515\/bchm3.1988.369.2.1009","journal-title":"Biol Chem Hoppe Seyler"},{"key":"9178_CR48","doi-asserted-by":"publisher","first-page":"7906","DOI":"10.4049\/jimmunol.0803624","volume":"182","author":"R Kahn","year":"2009","unstructured":"Kahn R, Hellmark T, Leeb-Lundberg LM, Akbari N, Todiras M, Olofsson T et al (2009) Neutrophil-derived proteinase 3 induces kallikrein-independent release of a novel vasoactive kinin. J Immunol 182:7906\u20137915. https:\/\/doi.org\/10.4049\/jimmunol.0803624","journal-title":"J Immunol"},{"key":"9178_CR49","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.phrs.2011.08.001","volume":"64","author":"L Gera","year":"2011","unstructured":"Gera L, Roy C, Bawolak MT, Bouthillier J, Adam A, Marceau F (2011) Met-Lys-bradykinin-Ser-Ser, a peptide produced by the neutrophil from kininogen, is metabolically activated by angiotensin converting enzyme in vascular tissue. Pharmacol Res 64:528\u2013534. https:\/\/doi.org\/10.1016\/j.phrs.2011.08.001","journal-title":"Pharmacol Res"},{"key":"9178_CR50","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1152\/ajplegacy.1962.203.2.261","volume":"203","author":"K Saameli","year":"1962","unstructured":"Saameli K, Eskes TK (1962) Bradykinin and cardiovascular system: estimation of half-life. Am J Physiol 203:261\u2013265. https:\/\/doi.org\/10.1152\/ajplegacy.1962.203.2.261","journal-title":"Am J Physiol"},{"key":"9178_CR51","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fmed.2020.00358","volume":"7","author":"F Marceau","year":"2020","unstructured":"Marceau F, Rivard GE, Gauthier JM, Binkley KE, Bonnefoy A, Boccon-Gibod I et al (2020) Measurement of bradykinin formation and degradation in blood plasma: Relevance for acquired angioedema associated with angiotensin converting enzyme inhibition and for hereditary angioedema due to factor XII or plasminogen gene variants. Front Med (Lausanne) 7:358. https:\/\/doi.org\/10.3389\/fmed.2020.00358","journal-title":"Front Med (Lausanne)"},{"issue":"Suppl 6","key":"9178_CR52","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/00005344-199015061-00005","volume":"15","author":"EG Erdos","year":"1990","unstructured":"Erd\u00f6s EG (1990) Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 15(Suppl 6):S20\u2013S24","journal-title":"J Cardiovasc Pharmacol"},{"key":"9178_CR53","doi-asserted-by":"publisher","unstructured":"Erd\u00f6s EG, Skidgel RA (1997) Metabolism of bradykinin by peptidases in health and disease. The Kinin System 111\u2013141. https:\/\/doi.org\/10.1016\/b978-012249340-9\/50009-7","DOI":"10.1016\/b978-012249340-9\/50009-7"},{"key":"9178_CR54","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/2151402a0","volume":"215","author":"HY Yang","year":"1967","unstructured":"Yang HY, Erdos EG (1967) Second kininase in human blood plasma. Nature 215:1402\u20131403. https:\/\/doi.org\/10.1038\/2151402a0","journal-title":"Nature"},{"key":"9178_CR55","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/s0196-9781(99)00020-0","volume":"20","author":"C Blais Jr","year":"1999","unstructured":"Blais C Jr., Marc-Aurele J, Simmons WH, Loute G, Thibault P, Skidgel RA et al (1999) Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides 20:421\u2013430. https:\/\/doi.org\/10.1016\/s0196-9781(99)00020-0","journal-title":"Peptides"},{"key":"9178_CR56","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/0006-2952(85)90787-7","volume":"34","author":"FE Palmieri","year":"1985","unstructured":"Palmieri FE, Petrelli JJ, Ward PE (1985) Vascular, plasma membrane aminopeptidase M. Metabolism of vasoactive peptides. Biochem Pharmacol 34:2309\u20132317. https:\/\/doi.org\/10.1016\/0006-2952(85)90787-7","journal-title":"Biochem Pharmacol"},{"key":"9178_CR57","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1124\/jpet.105.088799","volume":"314","author":"JP Fortin","year":"2005","unstructured":"Fortin JP, Gera L, Bouthillier J, Stewart JM, Adam A, Marceau F (2005) Endogenous aminopeptidase N decreases the potency of peptide agonists and antagonists of the kinin B1 receptors in the rabbit aorta. J Pharmacol Exp Ther 314:1169\u20131176. https:\/\/doi.org\/10.1124\/jpet.105.088799","journal-title":"J Pharmacol Exp Ther"},{"key":"9178_CR58","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1161\/01.cir.94.3.517","volume":"94","author":"AA Hasan","year":"1996","unstructured":"Hasan AA, Amenta S, Schmaier AH (1996) Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation 94:517\u2013528. https:\/\/doi.org\/10.1161\/01.cir.94.3.517","journal-title":"Circulation"},{"key":"9178_CR59","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.1097\/01.hjh.0000747380.40105.8d","volume":"39","author":"IM Souza-Silva","year":"2021","unstructured":"Souza-Silva IM, Paula C, Santos A, Oliveira V, Rocha I, Antunes M et al (2021) The Kallikrein-Kinin System is Falling Into Pieces: Bradykinin Fragments Are Biological Active Peptides. J Hypertens 39:e256. https:\/\/doi.org\/10.1097\/01.hjh.0000747380.40105.8d","journal-title":"J Hypertens"},{"key":"9178_CR60","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1124\/pr.57.1.2","volume":"57","author":"LM Leeb-Lundberg","year":"2005","unstructured":"Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL (2005) International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57:27\u201377. https:\/\/doi.org\/10.1124\/pr.57.1.2","journal-title":"Pharmacol Rev"},{"key":"9178_CR61","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/s1567-5769(02)00175-3","volume":"2","author":"C Cayla","year":"2002","unstructured":"Cayla C, Merino VF, Cabrini DA, Silva JA Jr., Pesquero JB, Bader M (2002) Structure of the mammalian kinin receptor gene locus. Int Immunopharmacol 2:1721\u20131727. https:\/\/doi.org\/10.1016\/s1567-5769(02)00175-3","journal-title":"Int Immunopharmacol"},{"key":"9178_CR62","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/1097-4644(20000901)78:3<351::AID-JCB1>3.0.CO;2-U","volume":"78","author":"X Zhou","year":"2000","unstructured":"Zhou X, Prado GN, Taylor L, Yang X, Polgar P (2000) Regulation of inducible bradykinin B1 receptor gene expression through absence of internalization and resensitization. J Cell Biochem 78:351\u2013362. https:\/\/doi.org\/10.1002\/1097-4644(20000901)78:3%3C351::aid-jcb1%3E3.0.co;2-u","journal-title":"J Cell Biochem"},{"key":"9178_CR63","doi-asserted-by":"publisher","first-page":"12475","DOI":"10.1074\/jbc.275.17.12475","volume":"275","author":"DA Ricupero","year":"2000","unstructured":"Ricupero DA, Romero JR, Rishikof DC, Goldstein RH (2000) Des-Arg(10)-kallidin engagement of the B1 receptor stimulates type I collagen synthesis via stabilization of connective tissue growth factor mRNA. J Biol Chem 275:12475\u201312480. https:\/\/doi.org\/10.1074\/jbc.275.17.12475","journal-title":"J Biol Chem"},{"key":"9178_CR64","doi-asserted-by":"publisher","first-page":"11420","DOI":"10.1074\/jbc.272.17.11420","volume":"272","author":"CE Austin","year":"1997","unstructured":"Austin CE, Faussner A, Robinson HE, Chakravarty S, Kyle DJ, Bathon JM et al (1997) Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways. J Biol Chem 272:11420\u201311425. https:\/\/doi.org\/10.1074\/jbc.272.17.11420","journal-title":"J Biol Chem"},{"key":"9178_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0014-2999(98)00165-4","volume":"348","author":"D Regoli","year":"1998","unstructured":"Regoli D, Nsa Allogho S, Rizzi A, Gobeil FJ (1998) Bradykinin receptors and their antagonists. Eur J Pharmacol 348:1\u201310. https:\/\/doi.org\/10.1016\/s0014-2999(98)00165-4","journal-title":"Eur J Pharmacol"},{"key":"9178_CR66","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1515\/BC.2001.018","volume":"382","author":"JF Hess","year":"2001","unstructured":"Hess JF, Hey PJ, Chen TB, O\u2019Brien J, Omalley SS, Pettibone DJ et al (2001) Molecular cloning and pharmacological characterization of the canine B1 and B2 bradykinin receptors. Biol Chem 382:123\u2013129. https:\/\/doi.org\/10.1515\/BC.2001.018","journal-title":"Biol Chem"},{"key":"9178_CR67","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.intimp.2007.10.001","volume":"8","author":"R Zubakova","year":"2008","unstructured":"Zubakova R, Gille A, Faussner A, Hilgenfeldt U (2008) Ca2\u2009+\u2009signalling of kinins in cells expressing rat, mouse and human B1\/B2-receptor. Int Immunopharmacol 8:276\u2013281. https:\/\/doi.org\/10.1016\/j.intimp.2007.10.001","journal-title":"Int Immunopharmacol"},{"key":"9178_CR68","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/med.2610100204","volume":"10","author":"RM Burch","year":"1990","unstructured":"Burch RM, Farmer SG, Steranka LR (1990) Bradykinin receptor antagonists. Med Res Rev 10:237\u2013269. https:\/\/doi.org\/10.1002\/med.2610100204","journal-title":"Med Res Rev"},{"key":"9178_CR69","doi-asserted-by":"publisher","first-page":"PL155","DOI":"10.1016\/s0024-3205(00)00420-3","volume":"66","author":"A Ueno","year":"2000","unstructured":"Ueno A, Naraba H, Ikeda Y, Ushikubi F, Murata T, Narumiya S et al (2000) Intrinsic prostacyclin contributes to exudation induced by bradykinin or carrageenin: a study on the paw edema induced in IP-receptor-deficient mice. Life Sci 66:PL155\u2013PL160. https:\/\/doi.org\/10.1016\/s0024-3205(00)00420-3","journal-title":"Life Sci"},{"key":"9178_CR70","doi-asserted-by":"publisher","first-page":"e84358","DOI":"10.1371\/journal.pone.0084358","volume":"9","author":"E Terzuoli","year":"2014","unstructured":"Terzuoli E, Meini S, Cucchi P, Catalani C, Cialdai C, Maggi CA et al (2014) Antagonism of bradykinin B2 receptor prevents inflammatory responses in human endothelial cells by quenching the NF-kB pathway activation. PLoS One 9:e84358. https:\/\/doi.org\/10.1371\/journal.pone.0084358","journal-title":"PLoS ONE"},{"key":"9178_CR71","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12016-016-8561-8","volume":"51","author":"BL Zuraw","year":"2016","unstructured":"Zuraw BL, Christiansen SC (2016) HAE Pathophysiology and Underlying Mechanisms. Clin Rev Allergy Immunol 51:216\u2013229. https:\/\/doi.org\/10.1007\/s12016-016-8561-8","journal-title":"Clin Rev Allergy Immunol"},{"key":"9178_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.11.006","author":"L Claesson-Welsh","year":"2021","unstructured":"Claesson-Welsh L, Dejana E, McDonald DM (2021) Permeability of the Endothelial Barrier: Identifying and Reconciling Controversies. Trends Mol Med 27:314\u2013331. https:\/\/doi.org\/10.1016\/j.molmed.2020.11.006","journal-title":"Trends Mol Med"},{"key":"9178_CR73","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/ncomms2199","volume":"3","author":"F Orsenigo","year":"2012","unstructured":"Orsenigo F, Giampietro C, Ferrari A, Corada M, Galaup A, Sigismund S et al (2012) Phosphorylation of VE-cadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo. Nat Commun 3:1208. https:\/\/doi.org\/10.1038\/ncomms2199","journal-title":"Nat Commun"},{"key":"9178_CR74","doi-asserted-by":"publisher","first-page":"H107","DOI":"10.1152\/ajpheart.00542.2005","volume":"290","author":"F Baffert","year":"2006","unstructured":"Baffert F, Le T, Thurston G, McDonald DM (2006) Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules. Am J Physiol Heart Circ Physiol 290:H107\u2013H118. https:\/\/doi.org\/10.1152\/ajpheart.00542.2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"9178_CR75","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1161\/01.hyp.35.6.1314","volume":"35","author":"ML Honing","year":"2000","unstructured":"Honing ML, Smits P, Morrison PJ, Rabelink TJ (2000) Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization. Hypertension 35:1314\u20131318. https:\/\/doi.org\/10.1161\/01.hyp.35.6.1314","journal-title":"Hypertension"},{"key":"9178_CR76","doi-asserted-by":"publisher","unstructured":"Freitas F, Tibirica E, Singh M, Fraser PA, Mann GE (2020) Redox regulation of microvascular permeability: IL-1beta potentiation of bradykinin-induced permeability is prevented by simvastatin. Antioxid (Basel) 9:1269. https:\/\/doi.org\/10.3390\/antiox9121269","DOI":"10.3390\/antiox9121269"},{"key":"9178_CR77","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/clpt.1991.212","volume":"50","author":"DC Manning","year":"1991","unstructured":"Manning DC, Raja SN, Meyer RA, Campbell JN (1991) Pain and hyperalgesia after intradermal injection of bradykinin in humans. Clin Pharmacol Ther 50:721\u2013729. https:\/\/doi.org\/10.1038\/clpt.1991.212","journal-title":"Clin Pharmacol Ther"},{"key":"9178_CR78","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jaci.2024.03.024","volume":"154","author":"A Reshef","year":"2024","unstructured":"Reshef A, Buttgereit T, Betschel SD, Caballero T, Farkas H, Grumach AS et al (2024) Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus. J Allergy Clin Immunol 154:398\u2013411e1. https:\/\/doi.org\/10.1016\/j.jaci.2024.03.024","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR79","doi-asserted-by":"publisher","unstructured":"Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ et al (2021) US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract 9:132\u2013150 e3. https:\/\/doi.org\/10.1016\/j.jaip.2020.08.046","DOI":"10.1016\/j.jaip.2020.08.046"},{"key":"9178_CR80","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygoren-Pursun E et al (2022) The international WAO\/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy 77:1961\u20131990. https:\/\/doi.org\/10.1111\/all.15214","journal-title":"Allergy"},{"key":"9178_CR81","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","volume":"351","author":"J Nussberger","year":"1998","unstructured":"Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A (1998) Plasma bradykinin in angio-oedema. Lancet 351:1693\u20131697. https:\/\/doi.org\/10.1016\/S0140-6736(97)09137-X","journal-title":"Lancet"},{"key":"9178_CR82","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJM200208223470820","volume":"347","author":"J Nussberger","year":"2002","unstructured":"Nussberger J, Cugno M, Cicardi M (2002) Bradykinin-mediated angioedema. N Engl J Med 347:621\u2013622. https:\/\/doi.org\/10.1056\/NEJM200208223470820","journal-title":"N Engl J Med"},{"key":"9178_CR83","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/0091-6749(83)90052-0","volume":"72","author":"T Fields","year":"1983","unstructured":"Fields T, Ghebrehiwet B, Kaplan AP (1983) Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of spontaneous formation of bradykinin. J Allergy Clin Immunol 72:54\u201360. https:\/\/doi.org\/10.1016\/0091-6749(83)90052-0","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR84","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJM198305053081802","volume":"308","author":"M Schapira","year":"1983","unstructured":"Schapira M, Silver LD, Scott CF, Schmaier AH, Prograis LJ Jr., Curd JG et al (1983) Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 308:1050\u20131053. https:\/\/doi.org\/10.1056\/NEJM198305053081802","journal-title":"N Engl J Med"},{"key":"9178_CR85","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1056\/NEJMoa0906393","volume":"363","author":"M Cicardi","year":"2010","unstructured":"Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M et al (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532\u2013541. https:\/\/doi.org\/10.1056\/NEJMoa0906393","journal-title":"N Engl J Med"},{"key":"9178_CR86","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.anai.2011.08.015","volume":"107","author":"WR Lumry","year":"2011","unstructured":"Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D et al (2011) Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 107:529\u2013537. https:\/\/doi.org\/10.1016\/j.anai.2011.08.015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9178_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(26)00004-9","author":"E Aygoren-Pursun","year":"2026","unstructured":"Aygoren-Pursun E, Stobiecki M, Valerieva A, Cancian M, Gompels M, Grigoriadou S et al (2026) Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol 13:E215\u2013E226. https:\/\/doi.org\/10.1016\/S2352-3026(26)00004-9","journal-title":"Lancet Haematol"},{"key":"9178_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00341-2","author":"M Maurer","year":"2026","unstructured":"Maurer M, Stobiecki M, Valerieva A, Hakl R, Staevska M, Bouillet L et al (2026) Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, doubleblind, placebo-controlled, phase 2 trial. Lancet Haematol 13:E200\u2013E214. https:\/\/doi.org\/10.1016\/S2352-3026(25)00341-2","journal-title":"Lancet Haematol"},{"key":"9178_CR89","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.bbrc.2006.03.092","volume":"343","author":"G Dewald","year":"2006","unstructured":"Dewald G, Bork K (2006) Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 343:1286\u20131289. https:\/\/doi.org\/10.1016\/j.bbrc.2006.03.092","journal-title":"Biochem Biophys Res Commun"},{"key":"9178_CR90","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1086\/509899","volume":"79","author":"S Cichon","year":"2006","unstructured":"Cichon S, Martin L, Hennies HC, Muller F, Van Driessche K, Karpushova A et al (2006) Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 79:1098\u20131104. https:\/\/doi.org\/10.1086\/509899","journal-title":"Am J Hum Genet"},{"key":"9178_CR91","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jaci.2009.03.038","volume":"124","author":"K Bork","year":"2009","unstructured":"Bork K, Wulff K, Hardt J, Witzke G, Staubach P (2009) Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 124:129\u2013134. https:\/\/doi.org\/10.1016\/j.jaci.2009.03.038","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR92","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.jaci.2016.02.021","volume":"138","author":"S de Maat","year":"2016","unstructured":"de Maat S, Bjorkqvist J, Suffritti C, Wiesenekker CP, Nagtegaal W, Koekman A et al (2016) Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. J Allergy Clin Immunol 138:1414\u201323e9. https:\/\/doi.org\/10.1016\/j.jaci.2016.02.021","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR93","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1182\/blood-2018-06-860270","volume":"133","author":"I Ivanov","year":"2019","unstructured":"Ivanov I, Matafonov A, Sun MF, Mohammed BM, Cheng Q, Dickeson SK et al (2019) A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain. Blood 133:1152\u20131163. https:\/\/doi.org\/10.1182\/blood-2018-06-860270","journal-title":"Blood"},{"key":"9178_CR94","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clim.2011.07.002","volume":"141","author":"K Bork","year":"2011","unstructured":"Bork K, Wulff K, Meinke P, Wagner N, Hardt J, Witzke G (2011) A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 141:31\u201335. https:\/\/doi.org\/10.1016\/j.clim.2011.07.002","journal-title":"Clin Immunol"},{"key":"9178_CR95","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.clim.2013.08.001","volume":"149","author":"N Kiss","year":"2013","unstructured":"Kiss N, Barabas E, Varnai K, Halasz A, Varga LA, Prohaszka Z et al (2013) Novel duplication in the F12 gene in a patient with recurrent angioedema. Clin Immunol 149:142\u2013145. https:\/\/doi.org\/10.1016\/j.clim.2013.08.001","journal-title":"Clin Immunol"},{"key":"9178_CR96","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3389\/fgene.2020.01033","volume":"11","author":"F Corvillo","year":"2020","unstructured":"Corvillo F, de la Morena-Barrio ME, Marcos-Bravo C, Lopez-Trascasa M, Vicente V, Emsley J et al (2020) The FXII c.-4T\u2009>\u2009C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant. Front Genet 11:1033. https:\/\/doi.org\/10.3389\/fgene.2020.01033","journal-title":"Front Genet"},{"key":"9178_CR97","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12016-025-09027-4","volume":"68","author":"BL Zuraw","year":"2025","unstructured":"Zuraw BL, Bork K, Bouillet L, Christiansen SC, Farkas H, Germenis AE et al (2025) Hereditary angioedema with normal C1 inhibitor: an updated international consensus paper on diagnosis, pathophysiology, and treatment. Clin Rev Allergy Immunol 68:24. https:\/\/doi.org\/10.1007\/s12016-025-09027-4","journal-title":"Clin Rev Allergy Immunol"},{"key":"9178_CR98","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13023-020-1334-8","volume":"15","author":"K Bork","year":"2020","unstructured":"Bork K, Wulff K, Witzke G, Machnig T, Hardt J (2020) Treatment of patients with hereditary angioedema with the c.988A\u2009>\u2009G (p.Lys330Glu) variant in the plasminogen gene. Orphanet J Rare Dis 15:52. https:\/\/doi.org\/10.1186\/s13023-020-1334-8","journal-title":"Orphanet J Rare Dis"},{"key":"9178_CR99","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bbrc.2017.12.060","volume":"498","author":"G Dewald","year":"2018","unstructured":"Dewald G (2018) A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 498:193\u2013198. https:\/\/doi.org\/10.1016\/j.bbrc.2017.12.060","journal-title":"Biochem Biophys Res Commun"},{"key":"9178_CR100","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1182\/blood.2022015610","volume":"139","author":"AP Kaplan","year":"2022","unstructured":"Kaplan AP (2022) Bradykinin formation by mutant plasminogen. Blood 139:2732\u20132733. https:\/\/doi.org\/10.1182\/blood.2022015610","journal-title":"Blood"},{"key":"9178_CR101","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/all.13270","volume":"73","author":"K Bork","year":"2018","unstructured":"Bork K, Wulff K, Steinmuller-Magin L, Braenne I, Staubach-Renz P, Witzke G et al (2018) Hereditary angioedema with a mutation in the plasminogen gene. Allergy 73:442\u2013450. https:\/\/doi.org\/10.1111\/all.13270","journal-title":"Allergy"},{"key":"9178_CR102","doi-asserted-by":"publisher","first-page":"1090732","DOI":"10.3389\/fphys.2022.1090732","volume":"13","author":"S Hintze","year":"2022","unstructured":"Hintze S, Mohl BS, Beyerl J, Wulff K, Wieser A, Bork K et al (2022) Mutant plasminogen in hereditary angioedema is bypassing FXII\/kallikrein to generate bradykinin. Front Physiol 13:1090732. https:\/\/doi.org\/10.3389\/fphys.2022.1090732","journal-title":"Front Physiol"},{"key":"9178_CR103","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/all.13869","volume":"74","author":"K Bork","year":"2019","unstructured":"Bork K, Wulff K, Rossmann H, Steinmuller-Magin L, Braenne I, Witzke G et al (2019) Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin. Allergy 74:2479\u20132481. https:\/\/doi.org\/10.1111\/all.13869","journal-title":"Allergy"},{"key":"9178_CR104","doi-asserted-by":"publisher","unstructured":"Loules G, Parsopoulou F, Zamanakou M, Csuka D, Bova M, Gonzalez-Quevedo T et al (2020) Deciphering the genetics of primary angioedema with normal levels of C1 inhibitor. J Clin Med 9:3402. https:\/\/doi.org\/10.3390\/jcm9113402","DOI":"10.3390\/jcm9113402"},{"key":"9178_CR105","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jaci.2021.01.011","volume":"148","author":"K Bork","year":"2021","unstructured":"Bork K, Wulff K, Mohl BS, Steinmuller-Magin L, Witzke G, Hardt J et al (2021) Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation. J Allergy Clin Immunol 148:1041\u20131048. https:\/\/doi.org\/10.1016\/j.jaci.2021.01.011","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR106","doi-asserted-by":"publisher","first-page":"e0121721","DOI":"10.1371\/journal.pone.0121721","volume":"10","author":"IZ Damasceno","year":"2015","unstructured":"Damasceno IZ, Melo KR, Nascimento FD, Souza DS, Araujo MS, Souza SE et al (2015) Bradykinin release avoids high molecular weight kininogen endocytosis. PLoS One 10:e0121721. https:\/\/doi.org\/10.1371\/journal.pone.0121721","journal-title":"PLoS ONE"},{"key":"9178_CR107","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1515\/BC.2009.016","volume":"390","author":"KR Melo","year":"2009","unstructured":"Melo KR, Gutierrez A, Nascimento FD, Araujo MK, Sampaio MU, Carmona AK et al (2009) Involvement of heparan sulfate proteoglycans in cellular uptake of high molecular weight kininogen. Biol Chem 390:145\u2013155. https:\/\/doi.org\/10.1515\/BC.2009.016","journal-title":"Biol Chem"},{"key":"9178_CR108","doi-asserted-by":"publisher","first-page":"100223","DOI":"10.1016\/j.jacig.2024.100223","volume":"3","author":"D Vincent","year":"2024","unstructured":"Vincent D, Parsopoulou F, Martin L, Gaboriaud C, Demongeot J, Loules G et al (2024) Hereditary angioedema with normal C1 inhibitor associated with carboxypeptidase N deficiency. J Allergy Clin Immunol Glob 3:100223. https:\/\/doi.org\/10.1016\/j.jacig.2024.100223","journal-title":"J Allergy Clin Immunol Glob"},{"key":"9178_CR109","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/jth.15551","volume":"20","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Zhao L, Shao Z, Declerck P, Leung LLK, Morser J (2022) Both plasma basic carboxypeptidases, carboxypeptidase B2 and carboxypeptidase N, regulate vascular leakage activity in mice. J Thromb Haemost 20:238\u2013244. https:\/\/doi.org\/10.1111\/jth.15551","journal-title":"J Thromb Haemost"},{"key":"9178_CR110","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1172\/JCI118315","volume":"96","author":"A Redlitz","year":"1995","unstructured":"Redlitz A, Tan AK, Eaton DL, Plow EF (1995) Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 96:2534\u20132538. https:\/\/doi.org\/10.1172\/JCI118315","journal-title":"J Clin Invest"},{"key":"9178_CR111","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/cea.13349","volume":"49","author":"M d\u2019Apolito","year":"2019","unstructured":"d\u2019Apolito M, Santacroce R, Colia AL, Cordisco G, Maffione AB, Margaglione M (2019) Angiopoietin-1 haploinsufficiency affects the endothelial barrier and causes hereditary angioedema. Clin Exp Allergy 49:626\u2013635. https:\/\/doi.org\/10.1111\/cea.13349","journal-title":"Clin Exp Allergy"},{"key":"9178_CR112","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1111\/all.14454","volume":"75","author":"A Ariano","year":"2020","unstructured":"Ariano A, D\u2019Apolito M, Bova M, Bellanti F, Loffredo S, D\u2019Andrea G et al (2020) A myoferlin gain-of-function variant associates with a new type of hereditary angioedema. Allergy 75:2989\u20132992. https:\/\/doi.org\/10.1111\/all.14454","journal-title":"Allergy"},{"key":"9178_CR113","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jaci.2024.05.017","volume":"154","author":"M D\u2019Apolito","year":"2024","unstructured":"D\u2019Apolito M, Santacroce R, Vazquez DO, Cordisco G, Fantini CA, D\u2019Andrea G et al (2024) DAB2IP associates with hereditary angioedema: Insights into the role of VEGF signaling in HAE pathophysiology. J Allergy Clin Immunol 154:698\u2013706. https:\/\/doi.org\/10.1016\/j.jaci.2024.05.017","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR114","doi-asserted-by":"publisher","first-page":"100906","DOI":"10.1016\/j.waojou.2024.100906","volume":"17","author":"P Giavina-Bianchi","year":"2024","unstructured":"Giavina-Bianchi P, Vivolo Aun M, Giavina-Bianchi M, Ribeiro AJ, Camara Agondi R, Motta AA et al (2024) Hereditary angioedema classification: Expanding knowledge by genotyping and endotyping. World Allergy Organ J 17:100906. https:\/\/doi.org\/10.1016\/j.waojou.2024.100906","journal-title":"World Allergy Organ J"},{"key":"9178_CR115","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13023-018-0815-5","volume":"13","author":"E Aygoren-Pursun","year":"2018","unstructured":"Aygoren-Pursun E, Magerl M, Maetzel A, Maurer M (2018) Epidemiology of bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis 13:73. https:\/\/doi.org\/10.1186\/s13023-018-0815-5","journal-title":"Orphanet J Rare Dis"},{"key":"9178_CR116","doi-asserted-by":"publisher","first-page":"837463","DOI":"10.3389\/falgy.2022.837463","volume":"3","author":"F Marceau","year":"2022","unstructured":"Marceau F, Rivard GE, H\u00e9bert J, Gauthier J, Bachelard H, Gangnus T et al (2022) Picomolar Sensitivity Analysis of Multiple Bradykinin-Related Peptides in the Blood Plasma of Patients With Hereditary Angioedema in Remission: A Pilot Study. Front Allergy 3:837463. https:\/\/doi.org\/10.3389\/falgy.2022.837463","journal-title":"Front Allergy"},{"key":"9178_CR117","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/cea.14122","volume":"52","author":"EJ Duckworth","year":"2022","unstructured":"Duckworth EJ, Murugesan N, Li L, Rushbrooke LJ, Lee DK, De Donatis GM et al (2022) Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema. Clin Exp Allergy 52:1059\u20131070. https:\/\/doi.org\/10.1111\/cea.14122","journal-title":"Clin Exp Allergy"},{"key":"9178_CR118","doi-asserted-by":"publisher","first-page":"1436855","DOI":"10.3389\/falgy.2024.1436855","volume":"5","author":"D Sexton","year":"2024","unstructured":"Sexton D, Faucette R, Rivera-Hernandez M, Kenniston JA, Papaioannou N, Cosic J et al (2024) A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema. Front Allergy 5:1436855. https:\/\/doi.org\/10.3389\/falgy.2024.1436855","journal-title":"Front Allergy"},{"key":"9178_CR119","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/cea.13219","volume":"48","author":"ML Lara-Marquez","year":"2018","unstructured":"Lara-Marquez ML, Christiansen SC, Riedl MA, Herschbach J, Zuraw BL (2018) Threshold-stimulated kallikrein activity distinguishes bradykinin- from histamine-mediated angioedema. Clin Exp Allergy 48:1429\u20131438. https:\/\/doi.org\/10.1111\/cea.13219","journal-title":"Clin Exp Allergy"},{"key":"9178_CR120","doi-asserted-by":"publisher","first-page":"101135","DOI":"10.1016\/j.waojou.2025.101135","volume":"18","author":"DK Lee","year":"2025","unstructured":"Lee DK, Ghannam A, Murugesan N, Vincent D, Dona M, Cohn DM et al (2025) A sensitive and specific assay to characterize plasma kallikrein activity in plasma from patients with hereditary angioedema. World Allergy Organ J 18:101135. https:\/\/doi.org\/10.1016\/j.waojou.2025.101135","journal-title":"World Allergy Organ J"},{"key":"9178_CR121","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.molimm.2021.06.009","volume":"136","author":"B Larrauri","year":"2021","unstructured":"Larrauri B, Hester CG, Jiang H, Miletic VD, Malbran A, Bork K et al (2021) Analysis of cold activation of the contact system in hereditary angioedema with normal C1 inhibitor. Mol Immunol 136:150\u2013160. https:\/\/doi.org\/10.1016\/j.molimm.2021.06.009","journal-title":"Mol Immunol"},{"key":"9178_CR122","doi-asserted-by":"publisher","first-page":"100505","DOI":"10.1016\/j.jacig.2025.100505","volume":"4","author":"J Chen","year":"2025","unstructured":"Chen J, Wu Y, Yu JJ, Chiao J, Yu J, Scarupa MD et al (2025) Bradykinin measurement by liquid chromatography tandem mass spectrometry in subjects with hereditary angioedema enhanced by cold activation. J Allergy Clin Immunol Glob 4:100505. https:\/\/doi.org\/10.1016\/j.jacig.2025.100505","journal-title":"J Allergy Clin Immunol Glob"},{"key":"9178_CR123","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.anai.2025.08.021","volume":"135","author":"E Pardali","year":"2025","unstructured":"Pardali E, Horv\u00e1th H, Domenig O, van Oyen D, Sexton D, Zahn G (2025) Clinical validation of a kinin biomarker assay to characterize bradykinin-mediated angioedema. Ann Allergy Asthma Immunol 135:S4. https:\/\/doi.org\/10.1016\/j.anai.2025.08.021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9178_CR124","doi-asserted-by":"publisher","first-page":"AB27","DOI":"10.1016\/j.jaci.2025.12.084","volume":"157","author":"E Pardali","year":"2026","unstructured":"Pardali E, Horv\u00e1th H, Yu J, Wan L, de Lange M, Domenig O et al (2026) A Novel Kinin Biomarker Assay For Characterization Of Different Types Of Bradykinin-Mediated Angioedema. J Allergy Clin Immunol 157:AB27. https:\/\/doi.org\/10.1016\/j.jaci.2025.12.084","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR125","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.jaip.2016.12.032","volume":"5","author":"A Zanichelli","year":"2017","unstructured":"Zanichelli A, Azin GM, Wu MA, Suffritti C, Maggioni L, Caccia S et al (2017) Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency. J Allergy Clin Immunol Pract 5:1307\u20131313. https:\/\/doi.org\/10.1016\/j.jaip.2016.12.032","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9178_CR126","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/j.1398-9995.2012.02853.x","volume":"67","author":"A Zanichelli","year":"2012","unstructured":"Zanichelli A, Bova M, Coerezza A, Petraroli A, Triggiani M, Cicardi M (2012) Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study. Allergy 67:1074\u20131077. https:\/\/doi.org\/10.1111\/j.1398-9995.2012.02853.x","journal-title":"Allergy"},{"key":"9178_CR127","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jaci.2024.03.007","volume":"154","author":"RS Petersen","year":"2024","unstructured":"Petersen RS, Fijen LM, Kelder JP, Cohn DM (2024) Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: A randomized-controlled trial. J Allergy Clin Immunol 154:179\u2013183. https:\/\/doi.org\/10.1016\/j.jaci.2024.03.007","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.07.033","author":"M de Lange","year":"2025","unstructured":"de Lange M, Petersen RS, Fijen LM, Cohn DM (2025) Long-term prophylactic treatment with deucrictibant for angioedema due to acquired C1-inhibitor deficiency. J Allergy Clin Immunol 156:P1650\u2013P1655. https:\/\/doi.org\/10.1016\/j.jaci.2025.07.033","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR129","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12245-017-0141-z","volume":"10","author":"JA Bernstein","year":"2017","unstructured":"Bernstein JA, Cremonesi P, Hoffmann TK, Hollingsworth J (2017) Angioedema in the emergency department: a practical guide to differential diagnosis and management. Int J Emerg Med 10:15. https:\/\/doi.org\/10.1186\/s12245-017-0141-z","journal-title":"Int J Emerg Med"},{"key":"9178_CR130","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jaip.2017.02.018","volume":"5","author":"A Banerji","year":"2017","unstructured":"Banerji A, Blumenthal KG, Lai KH, Zhou L (2017) Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record. J Allergy Clin Immunol Pract 5:744\u2013749. https:\/\/doi.org\/10.1016\/j.jaip.2017.02.018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9178_CR131","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1056\/NEJMoa1312524","volume":"372","author":"M Bas","year":"2015","unstructured":"Bas M, Greve J, Stelter K, Havel M, Strassen U, Rotter N et al (2015) A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 372:418\u2013425. https:\/\/doi.org\/10.1056\/NEJMoa1312524","journal-title":"N Engl J Med"},{"key":"9178_CR132","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaci.2016.09.051","volume":"140","author":"BT Straka","year":"2017","unstructured":"Straka BT, Ramirez CE, Byrd JB, Stone E, Woodard-Grice A, Nian H et al (2017) Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. J Allergy Clin Immunol 140:242\u20138e2. https:\/\/doi.org\/10.1016\/j.jaci.2016.09.051","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR133","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.jaip.2017.03.003","volume":"5","author":"R Sinert","year":"2017","unstructured":"Sinert R, Levy P, Bernstein JA, Body R, Sivilotti MLA, Moellman J et al (2017) Randomized trial of icatibant for angiotensin-converting enzyme inhibitor-induced upper airway angioedema. J Allergy Clin Immunol Pract 5:1402\u20139e3. https:\/\/doi.org\/10.1016\/j.jaip.2017.03.003","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9178_CR134","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1161\/01.hyp.38.2.183","volume":"38","author":"HM Siragy","year":"2001","unstructured":"Siragy HM, de Gasparo M, El-Kersh M, Carey RM (2001) Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 38:183\u2013186. https:\/\/doi.org\/10.1161\/01.hyp.38.2.183","journal-title":"Hypertension"},{"key":"9178_CR135","doi-asserted-by":"publisher","unstructured":"Smolinska S, Antolin-Amerigo D, Popescu FD (2023) Bradykinin metabolism and drug-induced angioedema. Int J Mol Sci 24:11649. https:\/\/doi.org\/10.3390\/ijms241411649","DOI":"10.3390\/ijms241411649"},{"key":"9178_CR136","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12948-021-00164-7","volume":"19","author":"N Cassano","year":"2021","unstructured":"Cassano N, Nettis E, Di Leo E, Ambrogio F, Vena GA, Foti C (2021) Angioedema associated with dipeptidyl peptidase-IV inhibitors. Clin Mol Allergy 19:24. https:\/\/doi.org\/10.1186\/s12948-021-00164-7","journal-title":"Clin Mol Allergy"},{"key":"9178_CR137","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/j.jaip.2025.05.060","volume":"13","author":"B Hong","year":"2025","unstructured":"Hong B, Lee H, Bae JH, Cho YM, Shin JY (2025) Risk for Angioedema With the Use of Dipeptidyl Peptidase 4 Inhibitors: A Population-Based Cohort Study. J Allergy Clin Immunol Pract 13:2025\u20132032. https:\/\/doi.org\/10.1016\/j.jaip.2025.05.060","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9178_CR138","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1161\/STROKEAHA.119.025260","volume":"50","author":"K Frohlich","year":"2019","unstructured":"Frohlich K, Macha K, Gerner ST, Bobinger T, Schmidt M, Dorfler A et al (2019) Angioedema in stroke patients with thrombolysis. Stroke 50:1682\u20131687. https:\/\/doi.org\/10.1161\/STROKEAHA.119.025260","journal-title":"Stroke"},{"key":"9178_CR139","doi-asserted-by":"publisher","first-page":"9360918","DOI":"10.1155\/2018\/9360918","volume":"2018","author":"M Sczepanski","year":"2018","unstructured":"Sczepanski M, Bozyk P (2018) Institutional incidence of severe tPA-induced angioedema in ischemic cerebral vascular accidents. Crit Care Res Pract 2018:9360918. https:\/\/doi.org\/10.1155\/2018\/9360918","journal-title":"Crit Care Res Pract"},{"key":"9178_CR140","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/joim.12962","volume":"286","author":"C Vigneron","year":"2019","unstructured":"Vigneron C, Lecluse A, Ronziere T, Bouillet L, Boccon-Gibod I, Gayet S et al (2019) Angioedema associated with thrombolysis for ischemic stroke: analysis of a case-control study. J Intern Med 286:702\u2013710. https:\/\/doi.org\/10.1111\/joim.12962","journal-title":"J Intern Med"},{"key":"9178_CR141","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1161\/STROKEAHA.116.013334","volume":"47","author":"F Myslimi","year":"2016","unstructured":"Myslimi F, Caparros F, Dequatre-Ponchelle N, Moulin S, Gautier S, Girardie P et al (2016) Orolingual angioedema during or after thrombolysis for cerebral ischemia. Stroke 47:1825\u20131830. https:\/\/doi.org\/10.1161\/STROKEAHA.116.013334","journal-title":"Stroke"},{"key":"9178_CR142","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1212\/WNL.0000000000004834","volume":"90","author":"C Benoit","year":"2018","unstructured":"Benoit C, Cantier M, Rodriguez-Regent C, Gout O, Obadia M (2018) Orolingual and abdominal angioedema post thrombolysis and thrombectomy. Neurology 90:140\u2013141. https:\/\/doi.org\/10.1212\/WNL.0000000000004834","journal-title":"Neurology"},{"key":"9178_CR143","doi-asserted-by":"publisher","unstructured":"Brown E, Campana C, Zimmerman J, Brooks S (2018) Icatibant for the treatment of orolingual angioedema following the administration of tissue plasminogen activator. Am J Emerg Med 36:1125 e1\u2013 e2. https:\/\/doi.org\/10.1016\/j.ajem.2018.03.018","DOI":"10.1016\/j.ajem.2018.03.018"},{"key":"9178_CR144","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.09.039","volume":"27","author":"E Cheong","year":"2018","unstructured":"Cheong E, Dodd L, Smith W, Kleinig T (2018) Icatibant as a potential treatment of life-threatening alteplase-induced angioedema. J Stroke Cerebrovasc Dis 27:e36\u2013e7. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2017.09.039","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"9178_CR145","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10072-021-05279-y","volume":"43","author":"M Mas-Serrano","year":"2022","unstructured":"Mas-Serrano M, Garcia-Pastor A, Iglesias-Mohedano AM, Diaz-Otero F, Vazquez-Alen P, Fernandez-Bullido Y et al (2022) Related factors with orolingual angioedema after intravenous alteplase in acute ischemic stroke: results from a single-center cohort and meta-analysis. Neurol Sci 43:441\u2013452. https:\/\/doi.org\/10.1007\/s10072-021-05279-y","journal-title":"Neurol Sci"},{"key":"9178_CR146","doi-asserted-by":"publisher","first-page":"e16173","DOI":"10.1111\/ene.16173","volume":"31","author":"A Theodorou","year":"2024","unstructured":"Theodorou A, Dimitriadou EM, Tzanetakos D, Bakola E, Chondrogianni M, Palaiodimou L et al (2024) Icatibant averting mechanical ventilation in acute ischemic stroke patient with alteplase-induced orolingual angioedema. Eur J Neurol 31:e16173. https:\/\/doi.org\/10.1111\/ene.16173","journal-title":"Eur J Neurol"},{"key":"9178_CR147","doi-asserted-by":"publisher","unstructured":"Wollmach AD, Zehnder D, Schwendinger M, Tarnutzer AA (2020) Unilateral orolingual angioedema in a patient with sarcoidosis after intravenous thrombolysis due to acute stroke without improvement after treatment with icatibant. BMJ Case Rep 13:e236643. https:\/\/doi.org\/10.1136\/bcr-2020-236643","DOI":"10.1136\/bcr-2020-236643"},{"key":"9178_CR148","doi-asserted-by":"publisher","first-page":"333","DOI":"10.18176\/jiaci.0996","volume":"34","author":"C Suffritti","year":"2024","unstructured":"Suffritti C, Calzari P, Depetri F, Griffini S, Grovetti E, Santacroce R et al (2024) Contact system activation and bradykinin generation in patients with idiopathic angioedema. J Investig Allergol Clin Immunol 34:333\u2013335. https:\/\/doi.org\/10.18176\/jiaci.0996","journal-title":"J Investig Allergol Clin Immunol"},{"key":"9178_CR149","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2500\/aap.2025.46.240091","volume":"46","author":"SC Christiansen","year":"2025","unstructured":"Christiansen SC, Zuraw BL (2025) Idiopathic non-mast cell angioedema: Treatment insights from global experts. Allergy Asthma Proc 46:38\u201344. https:\/\/doi.org\/10.2500\/aap.2025.46.240091","journal-title":"Allergy Asthma Proc"},{"key":"9178_CR150","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jaci.2013.06.015","volume":"132","author":"SG Brown","year":"2013","unstructured":"Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A et al (2013) Anaphylaxis: clinical patterns, mediator release, and severity. J Allergy Clin Immunol 132:1141\u20139e5. https:\/\/doi.org\/10.1016\/j.jaci.2013.06.015","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR151","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1182\/blood.V82.6.1732.1732","volume":"82","author":"PW van der Linden","year":"1993","unstructured":"van der Linden PW, Hack CE, Eerenberg AJ, Struyvenberg A, van der Zwan JK (1993) Activation of the contact system in insect-sting anaphylaxis: association with the development of angioedema and shock. Blood 82:1732\u20131739","journal-title":"Blood"},{"key":"9178_CR152","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.immuni.2011.02.008","volume":"34","author":"C Oschatz","year":"2011","unstructured":"Oschatz C, Maas C, Lecher B, Jansen T, Bjorkqvist J, Tradler T et al (2011) Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34:258\u2013268. https:\/\/doi.org\/10.1016\/j.immuni.2011.02.008","journal-title":"Immunity"},{"key":"9178_CR153","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaci.2014.07.057","volume":"135","author":"A Sala-Cunill","year":"2015","unstructured":"Sala-Cunill A, Bjorkqvist J, Senter R, Guilarte M, Cardona V, Labrador M et al (2015) Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol 135:1031\u201343e6. https:\/\/doi.org\/10.1016\/j.jaci.2014.07.057","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR154","doi-asserted-by":"crossref","unstructured":"Zhou X, Eren E, Path FRC, Rae W, Walls AF (2015) Bradykinin generation in acute allergic reactions and angioedema: roles of mast cell tryptase and chymase. J Allergy Clin Immunol 135:AB64","DOI":"10.1016\/j.jaci.2014.12.1142"},{"key":"9178_CR155","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1152\/jappl.1994.77.6.2675","volume":"77","author":"M Siebeck","year":"1994","unstructured":"Siebeck M, Cheronis JC, Fink E, Kohl J, Spies B, Spannagl M et al (1994) Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J Appl Physiol 77:2675\u20132680. https:\/\/doi.org\/10.1152\/jappl.1994.77.6.2675","journal-title":"J Appl Physiol"},{"key":"9178_CR156","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/imr.12632","volume":"282","author":"MK Church","year":"2018","unstructured":"Church MK, Kolkhir P, Metz M, Maurer M (2018) The role and relevance of mast cells in urticaria. Immunol Rev 282:232\u2013247. https:\/\/doi.org\/10.1111\/imr.12632","journal-title":"Immunol Rev"},{"key":"9178_CR157","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/cea.13558","volume":"50","author":"ZLM Hofman","year":"2020","unstructured":"Hofman ZLM, van den Elzen MT, Kuijpers J, de Maat S, Hack CE, Knulst AC et al (2020) Evidence for bradykinin release in chronic spontaneous urticaria. Clin Exp Allergy 50:343\u2013351. https:\/\/doi.org\/10.1111\/cea.13558","journal-title":"Clin Exp Allergy"},{"key":"9178_CR158","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1111\/jdv.14155","volume":"31","author":"R Asero","year":"2017","unstructured":"Asero R (2017) ACE inhibitors may interfere with omalizumab in chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 31:e358\u2013e9. https:\/\/doi.org\/10.1111\/jdv.14155","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9178_CR159","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/all.14674","volume":"76","author":"N Maltseva","year":"2021","unstructured":"Maltseva N, Borzova E, Fomina D, Bizjak M, Terhorst-Molawi D, Kosnik M et al (2021) Cold urticaria - What we know and what we do not know. Allergy 76:1077\u20131094. https:\/\/doi.org\/10.1111\/all.14674","journal-title":"Allergy"},{"key":"9178_CR160","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/archderm.1968.01610130073015","volume":"98","author":"FV DeLaus","year":"1968","unstructured":"DeLaus FV, Winkelmann RK (1968) Kinins in cold urticaria. Arch Dermatol 98:67\u201374","journal-title":"Arch Dermatol"},{"key":"9178_CR161","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/00015550252948284","volume":"82","author":"B Kranke","year":"2002","unstructured":"Kranke B, Mayr-Kanhauser S (2002) Cold urticaria and angiotensin converting enzyme inhibitor. Acta Derm Venereol 82:149\u2013150. https:\/\/doi.org\/10.1080\/00015550252948284","journal-title":"Acta Derm Venereol"},{"key":"9178_CR162","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41467-019-13984-8","volume":"11","author":"J Scheffel","year":"2020","unstructured":"Scheffel J, Mahnke NA, Hofman ZLM, Maat S, Wu J, Bonnekoh H et al (2020) Cold-induced urticarial autoinflammatory syndrome related to factor XII activation. Nat Commun 11:179. https:\/\/doi.org\/10.1038\/s41467-019-13984-8","journal-title":"Nat Commun"},{"key":"9178_CR163","doi-asserted-by":"publisher","first-page":"9625936","DOI":"10.1155\/2018\/9625936","volume":"2018","author":"J Song","year":"2018","unstructured":"Song J, Xian D, Yang L, Xiong X, Lai R, Zhong J (2018) Pruritus: Progress toward pathogenesis and treatment. Biomed Res Int 2018:9625936. https:\/\/doi.org\/10.1155\/2018\/9625936","journal-title":"Biomed Res Int"},{"key":"9178_CR164","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neulet.2014.03.062","volume":"579","author":"K Fu","year":"2014","unstructured":"Fu K, Qu L, Shimada SG, Nie H, LaMotte RH (2014) Enhanced scratching elicited by a pruritogen and an algogen in a mouse model of contact hypersensitivity. Neurosci Lett 579:190\u2013194. https:\/\/doi.org\/10.1016\/j.neulet.2014.03.062","journal-title":"Neurosci Lett"},{"key":"9178_CR165","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/sj.bjp.0702296","volume":"126","author":"I Hayashi","year":"1999","unstructured":"Hayashi I, Majima M (1999) Reduction of sodium deoxycholic acid-induced scratching behaviour by bradykinin B2 receptor antagonists. Br J Pharmacol 126:197\u2013204. https:\/\/doi.org\/10.1038\/sj.bjp.0702296","journal-title":"Br J Pharmacol"},{"key":"9178_CR166","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1152\/jn.01139.2002","volume":"89","author":"M Schmelz","year":"2003","unstructured":"Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjork HE, Handwerker HO (2003) Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol 89:2441\u20132448. https:\/\/doi.org\/10.1152\/jn.01139.2002","journal-title":"J Neurophysiol"},{"key":"9178_CR167","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.pain.2006.06.003","volume":"126","author":"M Hosogi","year":"2006","unstructured":"Hosogi M, Schmelz M, Miyachi Y, Ikoma A (2006) Bradykinin is a potent pruritogen in atopic dermatitis: a switch from pain to itch. Pain 126:16\u201323. https:\/\/doi.org\/10.1016\/j.pain.2006.06.003","journal-title":"Pain"},{"key":"9178_CR168","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s12264-017-0200-8","volume":"34","author":"C Moore","year":"2018","unstructured":"Moore C, Gupta R, Jordt SE, Chen Y, Liedtke WB (2018) Regulation of pain and itch by TRP channels. Neurosci Bull 34:120\u2013142. https:\/\/doi.org\/10.1007\/s12264-017-0200-8","journal-title":"Neurosci Bull"},{"key":"9178_CR169","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","volume":"8","author":"J Guo","year":"2023","unstructured":"Guo J, Zhang H, Lin W, Lu L, Su J, Chen X (2023) Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther 8:437. https:\/\/doi.org\/10.1038\/s41392-023-01655-6","journal-title":"Signal Transduct Target Ther"},{"key":"9178_CR170","doi-asserted-by":"publisher","unstructured":"Izaki S, Hibino T, Tanji O, Hsu PS, Segawa I, Kon S (1989) Modulation of plasma and tissue kallikreins in psoriasis vulgaris and psoriasis pustulosa. Dermatologica 179 Suppl 1:116\u2013117. https:\/\/doi.org\/10.1159\/000248461","DOI":"10.1159\/000248461"},{"key":"9178_CR171","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2133.1991.tb00567.x","volume":"124","author":"MT Poblete","year":"1991","unstructured":"Poblete MT, Reynolds NJ, Figueroa CD, Burton JL, Muller-Esterl W, Bhoola KD (1991) Tissue kallikrein and kininogen in human sweat glands and psoriatic skin. Br J Dermatol 124:236\u2013241. https:\/\/doi.org\/10.1111\/j.1365-2133.1991.tb00567.x","journal-title":"Br J Dermatol"},{"key":"9178_CR172","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/s0162-3109(99)00100-9","volume":"43","author":"E Schremmer-Danninger","year":"1999","unstructured":"Schremmer-Danninger E, Hermann A, Fink E, Fritz H, Roscher AA (1999) Identification and occurrence of mRNAs for components of the kallikrein-kinin system in human skin and in skin diseases. Immunopharmacology 43:287\u2013291. https:\/\/doi.org\/10.1016\/s0162-3109(99)00100-9","journal-title":"Immunopharmacology"},{"key":"9178_CR173","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/1523-1747.ep12460988","volume":"90","author":"T Hibino","year":"1988","unstructured":"Hibino T, Izaki S, Kimura H, Izaki M, Kon S (1988) Partial purification of plasma and tissue kallikreins in psoriatic epidermis. J Invest Dermatol 90:505\u2013510. https:\/\/doi.org\/10.1111\/1523-1747.ep12460988","journal-title":"J Invest Dermatol"},{"key":"9178_CR174","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000247119","volume":"188","author":"ED Kolosovsky","year":"1994","unstructured":"Kolosovsky ED (1994) Evaluation of different treatment methods in patients with psoriasis and content of kallikrein and kallikreinogen in blood plasma. Dermatology 188:140\u2013141. https:\/\/doi.org\/10.1159\/000247119","journal-title":"Dermatology"},{"key":"9178_CR175","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1111\/bph.15077","volume":"177","author":"BDS Soley","year":"2020","unstructured":"Soley BDS, Silva LM, Mendes D, Bafica A, Pesquero JB, Bader M et al (2020) B(1) and B(2) kinin receptor blockade improves psoriasis-like disease. Br J Pharmacol 177:3535\u20133551. https:\/\/doi.org\/10.1111\/bph.15077","journal-title":"Br J Pharmacol"},{"key":"9178_CR176","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1111\/bph.16428","volume":"181","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Chen Z, Guo J, Wan Q, Zhang Y, Li H et al (2024) Factor XII and prekallikrein promote microvascular inflammation and psoriasis in mice. Br J Pharmacol 181:3760\u20133778. https:\/\/doi.org\/10.1111\/bph.16428","journal-title":"Br J Pharmacol"},{"key":"9178_CR177","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/s0190-9622(08)81761-6","volume":"28","author":"P Gilleaudeau","year":"1993","unstructured":"Gilleaudeau P, Vallat VP, Carter DM, Gottlieb AB (1993) Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasis. J Am Acad Dermatol 28:490\u2013492. https:\/\/doi.org\/10.1016\/s0190-9622(08)81761-6","journal-title":"J Am Acad Dermatol"},{"key":"9178_CR178","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000247861","volume":"181","author":"R Wolf","year":"1990","unstructured":"Wolf R, Tamir A, Brenner S (1990) Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica 181:51\u201353. https:\/\/doi.org\/10.1159\/000247861","journal-title":"Dermatologica"},{"key":"9178_CR179","doi-asserted-by":"publisher","first-page":"10037","DOI":"10.1038\/s41598-021-89490-z","volume":"11","author":"G Song","year":"2021","unstructured":"Song G, Kim JY, Yoon HY, Yee J, Gwak HS (2021) A systematic review and meta-analysis of angiotensin-converting enzyme inhibitor use and psoriasis incidence. Sci Rep 11:10037. https:\/\/doi.org\/10.1038\/s41598-021-89490-z","journal-title":"Sci Rep"},{"key":"9178_CR180","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1172\/JCI112782","volume":"79","author":"SC Christiansen","year":"1987","unstructured":"Christiansen SC, Proud D, Cochrane CG (1987) Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects. J Clin Invest 79:188\u2013197. https:\/\/doi.org\/10.1172\/JCI112782","journal-title":"J Clin Invest"},{"key":"9178_CR181","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1164\/ajrccm\/145.4_Pt_1.900","volume":"145","author":"SC Christiansen","year":"1992","unstructured":"Christiansen SC, Proud D, Sarnoff RB, Juergens U, Cochrane CG, Zuraw BL (1992) Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects after endobronchial allergen challenge. Am Rev Respir Dis 145:900\u2013905. https:\/\/doi.org\/10.1164\/ajrccm\/145.4_Pt_1.900","journal-title":"Am Rev Respir Dis"},{"key":"9178_CR182","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/cea.12676","volume":"46","author":"FL Ricciardolo","year":"2016","unstructured":"Ricciardolo FL, Petecchia L, Sorbello V, Di Stefano A, Usai C, Massaglia GM et al (2016) Bradykinin B2 receptor expression in the bronchial mucosa of allergic asthmatics: the role of NF-kB. Clin Exp Allergy 46:428\u2013438. https:\/\/doi.org\/10.1111\/cea.12676","journal-title":"Clin Exp Allergy"},{"key":"9178_CR183","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1164\/ajrccm\/142.6_Pt_1.1367","volume":"142","author":"R Polosa","year":"1990","unstructured":"Polosa R, Holgate ST (1990) Comparative airway response to inhaled bradykinin, kallidin, and [des-Arg9]bradykinin in normal and asthmatic subjects. Am Rev Respir Dis 142:1367\u20131371. https:\/\/doi.org\/10.1164\/ajrccm\/142.6_Pt_1.1367","journal-title":"Am Rev Respir Dis"},{"key":"9178_CR184","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/0162-3109(96)00065-3","volume":"33","author":"AM Akbary","year":"1996","unstructured":"Akbary AM, Wirth KJ, Scholkens BA (1996) Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology 33:238\u2013242. https:\/\/doi.org\/10.1016\/0162-3109(96)00065-3","journal-title":"Immunopharmacology"},{"key":"9178_CR185","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejphar.2018.03.017","volume":"827","author":"FLM Ricciardolo","year":"2018","unstructured":"Ricciardolo FLM, Folkerts G, Folino A, Mognetti B (2018) Bradykinin in asthma: Modulation of airway inflammation and remodelling. Eur J Pharmacol 827:181\u2013188. https:\/\/doi.org\/10.1016\/j.ejphar.2018.03.017","journal-title":"Eur J Pharmacol"},{"key":"9178_CR186","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1745-9974-5-6","volume":"5","author":"TR Suguikawa","year":"2009","unstructured":"Suguikawa TR, Garcia CA, Martinez EZ, Vianna EO (2009) Cough and dyspnea during bronchoconstriction: comparison of different stimuli. Cough 5:6. https:\/\/doi.org\/10.1186\/1745-9974-5-6","journal-title":"Cough"},{"key":"9178_CR187","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1124\/jpet.115.230383","volume":"357","author":"MM Hewitt","year":"2016","unstructured":"Hewitt MM, Adams G Jr., Mazzone SB, Mori N, Yu L, Canning BJ (2016) Pharmacology of bradykinin-evoked coughing in guinea pigs. J Pharmacol Exp Ther 357:620\u2013628. https:\/\/doi.org\/10.1124\/jpet.115.230383","journal-title":"J Pharmacol Exp Ther"},{"key":"9178_CR188","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12931-019-1060-8","volume":"20","author":"F Al-Shamlan","year":"2019","unstructured":"Al-Shamlan F, El-Hashim AZ (2019) Bradykinin sensitizes the cough reflex via a B(2) receptor dependent activation of TRPV1 and TRPA1 channels through metabolites of cyclooxygenase and 12-lipoxygenase. Respir Res 20:110. https:\/\/doi.org\/10.1186\/s12931-019-1060-8","journal-title":"Respir Res"},{"key":"9178_CR189","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.1472-8206.2001.00008.x","volume":"15","author":"B Moreaux","year":"2001","unstructured":"Moreaux B, Advenier C, Gustin P (2001) Role of bradykinin and tachykinins in the potentiation by enalapril of coughing induced by citric acid in pigs. Fundam Clin Pharmacol 15:23\u201329. https:\/\/doi.org\/10.1046\/j.1472-8206.2001.00008.x","journal-title":"Fundam Clin Pharmacol"},{"key":"9178_CR190","doi-asserted-by":"publisher","first-page":"874114","DOI":"10.3389\/fmed.2022.874114","volume":"9","author":"SM Nur Husna","year":"2022","unstructured":"Nur Husna SM, Tan HT, Md Shukri N, Mohd Ashari NS, Wong KK (2022) Allergic rhinitis: a clinical and pathophysiological overview. Front Med (Lausanne) 9:874114. https:\/\/doi.org\/10.3389\/fmed.2022.874114","journal-title":"Front Med (Lausanne)"},{"key":"9178_CR191","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1172\/JCI111127","volume":"72","author":"D Proud","year":"1983","unstructured":"Proud D, Togias A, Naclerio RM, Crush SA, Norman PS, Lichtenstein LM (1983) Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest 72:1678\u20131685. https:\/\/doi.org\/10.1172\/JCI111127","journal-title":"J Clin Invest"},{"key":"9178_CR192","doi-asserted-by":"publisher","first-page":"977","DOI":"10.4049\/jimmunol.137.3.977","volume":"137","author":"CR Baumgarten","year":"1986","unstructured":"Baumgarten CR, Nichols RC, Naclerio RM, Lichtenstein LM, Norman PS, Proud D (1986) Plasma kallikrein during experimentally induced allergic rhinitis: role in kinin formation and contribution to TAME-esterase activity in nasal secretions. J Immunol 137:977\u2013982","journal-title":"J Immunol"},{"key":"9178_CR193","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.4049\/jimmunol.137.4.1323","volume":"137","author":"CR Baumgarten","year":"1986","unstructured":"Baumgarten CR, Nichols RC, Naclerio RM, Proud D (1986) Concentrations of glandular kallikrein in human nasal secretions increase during experimentally induced allergic rhinitis. J Immunol 137:1323\u20131328","journal-title":"J Immunol"},{"key":"9178_CR194","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1067\/mai.2001.111145","volume":"107","author":"P Turner","year":"2001","unstructured":"Turner P, Dear J, Scadding G, Foreman JC (2001) Role of kinins in seasonal allergic rhinitis: icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen. J Allergy Clin Immunol 107:105\u2013113. https:\/\/doi.org\/10.1067\/mai.2001.111145","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR195","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb14835.x","author":"CE Austin","year":"1994","unstructured":"Austin CE, Foreman JC, Scadding GK (1994) Reduction by Hoe 140, the B2 kinin receptor antagonist, of antigen-induced nasal blockage. Br J Pharmacol 111:969\u2009\u2013\u2009971. https:\/\/doi.org\/10.1111\/j.1476-5381.1994.tb14835.x","journal-title":"Br J Pharmacol"},{"key":"9178_CR196","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1164\/ajrccm\/137.3.613","volume":"137","author":"D Proud","year":"1988","unstructured":"Proud D, Reynolds CJ, Lacapra S, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM (1988) Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis 137:613\u2013616. https:\/\/doi.org\/10.1164\/ajrccm\/137.3.613","journal-title":"Am Rev Respir Dis"},{"key":"9178_CR197","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00405-006-0161-4","volume":"264","author":"P Sheahan","year":"2007","unstructured":"Sheahan P, McConn-Walsh R, Walsh M, Costello RW (2007) Subjects with non-allergic non-infectious perennial rhinitis do not show nasal hyper-responsiveness to bradykinin. Eur Arch Otorhinolaryngol 264:33\u201337. https:\/\/doi.org\/10.1007\/s00405-006-0161-4","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"9178_CR198","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJM199810293391804","volume":"339","author":"JV Gainer","year":"1998","unstructured":"Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ (1998) Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339:1285\u20131292. https:\/\/doi.org\/10.1056\/NEJM199810293391804","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"9178_CR199","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/00005344-200109011-00004","volume":"37","author":"F Enseleit","year":"2001","unstructured":"Enseleit F, Hurlimann D, Luscher TF (2001) Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. J Cardiovasc Pharmacol 37(Suppl 1):S21\u201330. https:\/\/doi.org\/10.1097\/00005344-200109011-00004","journal-title":"J Cardiovasc Pharmacol"},{"key":"9178_CR200","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/hr.2010.82","volume":"33","author":"AJ Manolis","year":"2010","unstructured":"Manolis AJ, Marketou ME, Gavras I, Gavras H (2010) Cardioprotective properties of bradykinin: role of the B(2) receptor. Hypertens Res 33:772\u2013777. https:\/\/doi.org\/10.1038\/hr.2010.82","journal-title":"Hypertens Res"},{"key":"9178_CR201","doi-asserted-by":"crossref","unstructured":"Alhenc-Gelas F, Bouby N, Richer-Giudicelli C (2025) Bradykinin in cardiovascular physiology and disease. Molecular Mediators in Health and Disease: How Cells Communicate, Bradykinin. Academic, pp 283\u2013297","DOI":"10.1016\/B978-0-443-28907-1.00016-5"},{"key":"9178_CR202","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0014-2999(97)83027-0","volume":"328","author":"K Kaszala","year":"1997","unstructured":"Kaszala K, Vegh A, Papp JG, Parratt JR (1997) Modification by bradykinin B2 receptor blockade of protection by pacing against ischaemia-induced arrhythmias. Eur J Pharmacol 328:51\u201360. https:\/\/doi.org\/10.1016\/s0014-2999(97)83027-0","journal-title":"Eur J Pharmacol"},{"key":"9178_CR203","first-page":"541","volume":"5","author":"W Sun","year":"1994","unstructured":"Sun W, Wainwright CL (1994) The potential antiarrhythmic effects of exogenous and endogenous bradykinin in the ischaemic rat heart in vivo. Coron Artery Dis 5:541\u2013550","journal-title":"Coron Artery Dis"},{"key":"9178_CR204","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s0162-3109(99)00155-1","volume":"44","author":"SA Abbas","year":"1999","unstructured":"Abbas SA, Sharma JN, Yusof AP (1999) The effect of bradykinin and its antagonist on survival time after coronary artery occlusion in hypertensive rats. Immunopharmacology 44:93\u201398. https:\/\/doi.org\/10.1016\/s0162-3109(99)00155-1","journal-title":"Immunopharmacology"},{"key":"9178_CR205","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/01.HYP.0000214867.35632.0e","volume":"47","author":"CF Xia","year":"2006","unstructured":"Xia CF, Smith RS Jr., Shen B, Yang ZR, Borlongan CV, Chao L et al (2006) Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension 47:752\u2013761. https:\/\/doi.org\/10.1161\/01.HYP.0000214867.35632.0e","journal-title":"Hypertension"},{"key":"9178_CR206","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10557-016-6661-6","volume":"30","author":"Y Song","year":"2016","unstructured":"Song Y, Shan JG, Xue Z, Wang SY, Xu H, Liu Y et al (2016) Remote postconditioning induced by trauma protects the mouse heart against ischemia reperfusion injury. Involvement of the neural pathway and molecular mechanisms. Cardiovasc Drugs Ther 30:271\u2013280. https:\/\/doi.org\/10.1007\/s10557-016-6661-6","journal-title":"Cardiovasc Drugs Ther"},{"key":"9178_CR207","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1161\/01.hyp.30.3.735","volume":"30","author":"XP Yang","year":"1997","unstructured":"Yang XP, Liu YH, Scicli GM, Webb CR, Carretero OA (1997) Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia\/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 30:735\u2013740. https:\/\/doi.org\/10.1161\/01.hyp.30.3.735","journal-title":"Hypertension"},{"key":"9178_CR208","doi-asserted-by":"publisher","unstructured":"Kleinschnitz C, Austinat M, Bader M, Renne T, Stoll G (2008) Deficiency of bradykinin receptor B2 is not detrimental in experimental stroke. Hypertension 51:e41. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.109090","DOI":"10.1161\/HYPERTENSIONAHA.107.109090"},{"key":"9178_CR209","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/STROKEAHA.108.526673","volume":"40","author":"M Austinat","year":"2009","unstructured":"Austinat M, Braeuninger S, Pesquero JB, Brede M, Bader M, Stoll G et al (2009) Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 40:285\u2013293. https:\/\/doi.org\/10.1161\/STROKEAHA.108.526673","journal-title":"Stroke"},{"key":"9178_CR210","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1006\/jsre.1996.0187","volume":"62","author":"TF Hoffmann","year":"1996","unstructured":"Hoffmann TF, Steinbauer M, Waldner H, Messmer K (1996) Exogenous bradykinin enhances ischemia\/reperfusion injury of pancreas in rats. J Surg Res 62:144\u2013151. https:\/\/doi.org\/10.1006\/jsre.1996.0187","journal-title":"J Surg Res"},{"key":"9178_CR211","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/08941939.2015.1041656","volume":"29","author":"LR Mendonca","year":"2016","unstructured":"Mendonca LR, Joviliano EE, Ramalho FS, Ramalho LN, Evora PR, Piccinato CE (2016) Bradykinin Impairs and HOE 140 does not Protect Rat Hindlimb Skeletal Muscle Against Tourniquet-induced Reperfusion Injury. J Invest Surg 29:13\u201319. https:\/\/doi.org\/10.3109\/08941939.2015.1041656","journal-title":"J Invest Surg"},{"key":"9178_CR212","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1211\/0022357021314","volume":"55","author":"KK Veeravalli","year":"2003","unstructured":"Veeravalli KK, Akula A, Kota MK (2003) Nitric oxide- and prostaglandin-mediated cardioprotection by bradykinin in myocardial ischemia and reperfusion injury. Pol J Pharmacol 55:1021\u20131029","journal-title":"Pol J Pharmacol"},{"key":"9178_CR213","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1161\/01.hyp.35.1.25","volume":"35","author":"H Yoshida","year":"2000","unstructured":"Yoshida H, Zhang JJ, Chao L, Chao J (2000) Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 35:25\u201331. https:\/\/doi.org\/10.1161\/01.hyp.35.1.25","journal-title":"Hypertension"},{"key":"9178_CR214","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cardiores.2006.10.014","volume":"73","author":"HJ Li","year":"2007","unstructured":"Li HJ, Yin H, Yao YY, Shen B, Bader M, Chao L et al (2007) Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res 73:130\u2013142. https:\/\/doi.org\/10.1016\/j.cardiores.2006.10.014","journal-title":"Cardiovasc Res"},{"key":"9178_CR215","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1476-5381.1993.tb12802.x","volume":"108","author":"R Chahine","year":"1993","unstructured":"Chahine R, Adam A, Yamaguchi N, Gaspo R, Regoli D, Nadeau R (1993) Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor. Br J Pharmacol 108:318\u2013322. https:\/\/doi.org\/10.1111\/j.1476-5381.1993.tb12802.x","journal-title":"Br J Pharmacol"},{"key":"9178_CR216","doi-asserted-by":"publisher","first-page":"H812","DOI":"10.1152\/ajpheart.1999.277.2.H812","volume":"277","author":"W Wang","year":"1999","unstructured":"Wang W, Schultz HD, Ma R (1999) Cardiac sympathetic afferent sensitivity is enhanced in heart failure. Am J Physiol 277:H812\u2013817. https:\/\/doi.org\/10.1152\/ajpheart.1999.277.2.H812","journal-title":"Am J Physiol"},{"key":"9178_CR217","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0022-3565(25)22425-9","volume":"270","author":"TM Wall","year":"1994","unstructured":"Wall TM, Sheehy R, Hartman JC (1994) Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 270:681\u2013689.","journal-title":"J Pharmacol Exp Ther"},{"key":"9178_CR218","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1161\/01.cir.102.18.2190","volume":"102","author":"NJ Brown","year":"2000","unstructured":"Brown NJ, Gainer JV, Murphey LJ, Vaughan DE (2000) Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 102:2190\u20132196. https:\/\/doi.org\/10.1161\/01.cir.102.18.2190","journal-title":"Circulation"},{"key":"9178_CR219","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.V66.4.835.835","volume":"66","author":"D Smith","year":"1985","unstructured":"Smith D, Gilbert M, Owen WG (1985) Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 66:835\u2013839","journal-title":"Blood"},{"key":"9178_CR220","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1182\/blood-2006-01-0094","volume":"108","author":"Z Shariat-Madar","year":"2006","unstructured":"Shariat-Madar Z, Mahdi F, Warnock M, Homeister JW, Srikanth S, Krijanovski Y et al (2006) Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood 108:192\u2013199. https:\/\/doi.org\/10.1182\/blood-2006-01-0094","journal-title":"Blood"},{"key":"9178_CR221","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1182\/blood-2012-09-459156","volume":"121","author":"C Fang","year":"2013","unstructured":"Fang C, Stavrou E, Schmaier AA, Grobe N, Morris M, Chen A et al (2013) Angiotensin 1\u20137 and Mas decrease thrombosis in Bdkrb2-\/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. Blood 121:3023\u20133032. https:\/\/doi.org\/10.1182\/blood-2012-09-459156","journal-title":"Blood"},{"key":"9178_CR222","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.jaci.2018.06.014","volume":"142","author":"H Cao","year":"2018","unstructured":"Cao H, Biondo M, Lioe H, Busfield S, Rayzman V, Nieswandt B et al (2018) Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation. J Allergy Clin Immunol 142:1355\u20131358. https:\/\/doi.org\/10.1016\/j.jaci.2018.06.014","journal-title":"J Allergy Clin Immunol"},{"key":"9178_CR223","doi-asserted-by":"publisher","first-page":"222ra17","DOI":"10.1126\/scitranslmed.3006804","volume":"6","author":"M Larsson","year":"2014","unstructured":"Larsson M, Rayzman V, Nolte MW, Nickel KF, Bjorkqvist J, Jamsa A et al (2014) A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 6:222ra17. https:\/\/doi.org\/10.1126\/scitranslmed.3006804","journal-title":"Sci Transl Med"},{"key":"9178_CR224","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1113\/JP282568","volume":"600","author":"JA Lang","year":"2022","unstructured":"Lang JA, Kim J (2022) Remote ischaemic preconditioning - translating cardiovascular benefits to humans. J Physiol 600:3053\u20133067. https:\/\/doi.org\/10.1113\/JP282568","journal-title":"J Physiol"},{"key":"9178_CR225","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12265-018-9813-1","volume":"11","author":"JH Rosenberg","year":"2018","unstructured":"Rosenberg JH, Werner JH, Moulton MJ, Agrawal DK (2018) Current modalities and mechanisms underlying cardioprotection by ischemic conditioning. J Cardiovasc Transl Res 11:292\u2013307. https:\/\/doi.org\/10.1007\/s12265-018-9813-1","journal-title":"J Cardiovasc Transl Res"},{"key":"9178_CR226","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1136\/heartjnl-2011-300323","volume":"97","author":"CM Pedersen","year":"2011","unstructured":"Pedersen CM, Schmidt MR, Barnes G, Botker HE, Kharbanda RK, Newby DE et al (2011) Bradykinin does not mediate remote ischaemic preconditioning or ischaemia-reperfusion injury in vivo in man. Heart 97:1857\u20131861. https:\/\/doi.org\/10.1136\/heartjnl-2011-300323","journal-title":"Heart"},{"key":"9178_CR227","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1161\/01.cir.100.3.268","volume":"100","author":"AP Davie","year":"1999","unstructured":"Davie AP, Dargie HJ, McMurray JJ (1999) Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation 100:268\u2013273. https:\/\/doi.org\/10.1161\/01.cir.100.3.268","journal-title":"Circulation"},{"key":"9178_CR228","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1161\/hc4301.098252","volume":"104","author":"FN Witherow","year":"2001","unstructured":"Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE (2001) Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 104:2177\u20132181. https:\/\/doi.org\/10.1161\/hc4301.098252","journal-title":"Circulation"},{"key":"9178_CR229","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/01.mej.0000228442.10158.5e","volume":"14","author":"KR Krmpotic","year":"2007","unstructured":"Krmpotic KR, Fernandes CM (2007) Anaphylactoid reaction to recombinant tissue plasminogen activator. Eur J Emerg Med 14:60\u201361. https:\/\/doi.org\/10.1097\/01.mej.0000228442.10158.5e","journal-title":"Eur J Emerg Med"},{"key":"9178_CR230","doi-asserted-by":"publisher","unstructured":"Zarar A, Khan AA, Adil MM, Qureshi AI (2014) Anaphylactic shock associated with intravenous thrombolytics. Am J Emerg Med 32:113-e3-5. https:\/\/doi.org\/10.1016\/j.ajem.2013.08.046","DOI":"10.1016\/j.ajem.2013.08.046"},{"key":"9178_CR231","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1161\/STROKEAHA.124.047060","volume":"55","author":"EM Hutten","year":"2024","unstructured":"Hutten EM, van de Ven A, Mencke R, Pleijhuis RG (2024) Angioedema after use of recombinant tissue-type plasminogen activators in stroke. Stroke 55:2193\u20132197. https:\/\/doi.org\/10.1161\/STROKEAHA.124.047060","journal-title":"Stroke"},{"key":"9178_CR232","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1046\/j.1523-1755.1999.0550031097.x","volume":"55","author":"JL Renaux","year":"1999","unstructured":"Renaux JL, Thomas M, Crost T, Loughraieb N, Vantard G (1999) Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH. Kidney Int 55:1097\u20131103. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.0550031097.x","journal-title":"Kidney Int"},{"key":"9178_CR233","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12882-023-03192-4","volume":"24","author":"JL Gamboa","year":"2023","unstructured":"Gamboa JL, Mambungu CA, Clagett AR, Nian H, Yu C, Ikizler TA et al (2023) Bradykinin B(2) receptor blockade and intradialytic hypotension. BMC Nephrol 24:134. https:\/\/doi.org\/10.1186\/s12882-023-03192-4","journal-title":"BMC Nephrol"},{"key":"9178_CR234","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/sj.jcbfm.9600096","volume":"25","author":"M Groger","year":"2005","unstructured":"Groger M, Lebesgue D, Pruneau D, Relton J, Kim SW, Nussberger J et al (2005) Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 25:978\u2013989. https:\/\/doi.org\/10.1038\/sj.jcbfm.9600096","journal-title":"J Cereb Blood Flow Metab"},{"key":"9178_CR235","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/jcbfm.2009.196","volume":"30","author":"R Trabold","year":"2010","unstructured":"Trabold R, Eros C, Zweckberger K, Relton J, Beck H, Nussberger J et al (2010) The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice. J Cereb Blood Flow Metab 30:130\u2013139. https:\/\/doi.org\/10.1038\/jcbfm.2009.196","journal-title":"J Cereb Blood Flow Metab"},{"key":"9178_CR236","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1089\/089771502320317104","volume":"19","author":"J Kaplanski","year":"2002","unstructured":"Kaplanski J, Pruneau D, Asa I, Artru AA, Azez A, Ivashkova Y et al (2002) LF 16\u20130687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. J Neurotrauma 19:953\u2013964. https:\/\/doi.org\/10.1089\/089771502320317104","journal-title":"J Neurotrauma"},{"key":"9178_CR237","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1089\/neu.2012.2774","volume":"30","author":"M Kunz","year":"2013","unstructured":"Kunz M, Nussberger J, Holtmannspotter M, Bitterling H, Plesnila N, Zausinger S (2013) Bradykinin in blood and cerebrospinal fluid after acute cerebral lesions: correlations with cerebral edema and intracranial pressure. J Neurotrauma 30:1638\u20131644. https:\/\/doi.org\/10.1089\/neu.2012.2774","journal-title":"J Neurotrauma"},{"key":"9178_CR238","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s007010050181","volume":"140","author":"PK Narotam","year":"1998","unstructured":"Narotam PK, Rodell TC, Nadvi SS, Bhoola KD, Troha JM, Parbhoosingh R et al (1998) Traumatic brain contusions: a clinical role for the kinin antagonist CP-0127. Acta Neurochir (Wien) 140:793\u2013802 discussion\u2009\u2013\u20093. https:\/\/doi.org\/10.1007\/s007010050181","journal-title":"Acta Neurochir (Wien)"},{"key":"9178_CR239","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1089\/neu.1999.16.431","volume":"16","author":"A Marmarou","year":"1999","unstructured":"Marmarou A, Nichols J, Burgess J, Newell D, Troha J, Burnham D et al (1999) Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. J Neurotrauma 16:431\u2013444. https:\/\/doi.org\/10.1089\/neu.1999.16.431","journal-title":"J Neurotrauma"},{"key":"9178_CR240","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1089\/neu.2005.22.1444","volume":"22","author":"A Marmarou","year":"2005","unstructured":"Marmarou A, Guy M, Murphey L, Roy F, Layani L, Combal JP et al (2005) A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury. J Neurotrauma 22:1444\u20131455. https:\/\/doi.org\/10.1089\/neu.2005.22.1444","journal-title":"J Neurotrauma"},{"key":"9178_CR241","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1745-6215-10-109","volume":"10","author":"H Shakur","year":"2009","unstructured":"Shakur H, Andrews P, Asser T, Balica L, Boeriu C, Quintero JD et al (2009) The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials 10:109. https:\/\/doi.org\/10.1186\/1745-6215-10-109","journal-title":"Trials"},{"key":"9178_CR242","doi-asserted-by":"publisher","unstructured":"Tabassum A, Iqbal MS, Sultan S, Alhuthali RA, Alshubaili DI, Sayyam RS et al (2022) Dysregulated Bradykinin: Mystery in the Pathogenesis of COVID-19. Mediators Inflamm 2022:7423537. https:\/\/doi.org\/10.1155\/2022\/7423537","DOI":"10.1155\/2022\/7423537"},{"key":"9178_CR243","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1055\/s-0040-1712960","volume":"46","author":"S de Maat","year":"2020","unstructured":"de Maat S, de Mast Q, Danser AHJ, van de Veerdonk FL, Maas C (2020) Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection. Semin Thromb Hemost 46:835\u2013837. https:\/\/doi.org\/10.1055\/s-0040-1712960","journal-title":"Semin Thromb Hemost"},{"key":"9178_CR244","doi-asserted-by":"publisher","unstructured":"Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK et al (2020) A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. eLife 9:e59177. https:\/\/doi.org\/10.7554\/eLife.59177","DOI":"10.7554\/eLife.59177"},{"key":"9178_CR245","doi-asserted-by":"publisher","unstructured":"van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JW, de Mast Q, Bruggemann RJ et al (2020) Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife 9:e57555. https:\/\/doi.org\/10.7554\/eLife.57555","DOI":"10.7554\/eLife.57555"},{"key":"9178_CR246","doi-asserted-by":"publisher","first-page":"e2017708","DOI":"10.1001\/jamanetworkopen.2020.17708","volume":"3","author":"FL van de Veerdonk","year":"2020","unstructured":"van de Veerdonk FL, Kouijzer IJE, de Nooijer AH, van der Hoeven HG, Maas C, Netea MG et al (2020) Outcomes associated with use of a Kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw Open 3:e2017708. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.17708","journal-title":"JAMA Netw Open"},{"key":"9178_CR247","doi-asserted-by":"publisher","first-page":"451","DOI":"10.18176\/jiaci.0659","volume":"31","author":"D Pecori","year":"2021","unstructured":"Pecori D, Della Siega P, Sozio E, Barbano E, Mazzoran L, Zanichelli A et al (2021) Icatibant in severe acute respiratory syndrome coronavirus 2 infection: a case report. J Investig Allergol Clin Immunol 31:451\u2013452. https:\/\/doi.org\/10.18176\/jiaci.0659","journal-title":"J Investig Allergol Clin Immunol"},{"key":"9178_CR248","doi-asserted-by":"publisher","unstructured":"Mansour E, Palma AC, Ulaf RG, Ribeiro LC, Bernardes AF, Nunes TA et al (2021) Safety and outcomes associated with the pharmacological inhibition of the Kinin-Kallikrein system in severe COVID-19. Viruses 13:309. https:\/\/doi.org\/10.3390\/v13020309","DOI":"10.3390\/v13020309"},{"key":"9178_CR249","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/cid\/ciac984","volume":"76","author":"P Malchair","year":"2023","unstructured":"Malchair P, Giol J, Garcia V, Rodriguez O, Ruibal JC, Zarauza A et al (2023) Three-day icatibant on top of standard care in patients with coronavirus disease 2019 pneumonia: a randomized, open-label, phase 2, proof-of-concept trial. Clin Infect Dis 76:1784\u20131792. https:\/\/doi.org\/10.1093\/cid\/ciac984","journal-title":"Clin Infect Dis"},{"key":"9178_CR250","doi-asserted-by":"publisher","first-page":"101889","DOI":"10.1016\/j.eclinm.2023.101889","volume":"58","author":"COVID I-Spy","year":"2023","unstructured":"I-Spy COVID, Consortium (2023) Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial. EClinicalMedicine 58:101889. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101889","journal-title":"EClinicalMedicine"},{"key":"9178_CR251","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/all.13103","volume":"72","author":"A Zanichelli","year":"2017","unstructured":"Zanichelli A, Maurer M, Aberer W, Caballero T, Longhurst HJ, Bouillet L et al (2017) Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice. Allergy 72:994\u2013998. https:\/\/doi.org\/10.1111\/all.13103","journal-title":"Allergy"},{"key":"9178_CR252","unstructured":"Takeda Pharmaceuticals International AG (2008) Firazyr (icatibant) summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/firazyr-epar-product-information_en.pdf Accessed Sept 17 2025"},{"key":"9178_CR253","unstructured":"Takeda Pharmaceutical Company Limited (2021) Firazyr Label package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022150Orig1s014lbl.pdf. Accessed Sept 17 2025"},{"key":"9178_CR254","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/cea.14206","volume":"52","author":"M Maurer","year":"2022","unstructured":"Maurer M, Aberer W, Caballero T, Bouillet L, Grumach AS, Botha J et al (2022) The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema. Clin Exp Allergy 52:1048\u20131058. https:\/\/doi.org\/10.1111\/cea.14206","journal-title":"Clin Exp Allergy"},{"key":"9178_CR255","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1007\/s00277-025-06544-2","volume":"104","author":"C Ge","year":"2025","unstructured":"Ge C, He Y, Huang F, Zeng Z (2025) Lymphoma and Long-Term cardiovascular disease risk: A comprehensive analysis from the UK biobank. Ann Hematol 104:5797\u20135808. https:\/\/doi.org\/10.1007\/s00277-025-06544-2","journal-title":"Ann Hematol"},{"key":"9178_CR256","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood.2019003893","volume":"139","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, McCullough KB, Habermann TM (2022) How I treat cardiovascular complications in patients with lymphoid malignancies. Blood 139:1501\u20131516. https:\/\/doi.org\/10.1182\/blood.2019003893","journal-title":"Blood"},{"key":"9178_CR257","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.amjcard.2023.11.039","volume":"212","author":"JH Yong","year":"2024","unstructured":"Yong JH, Mai AS, Matetic A, Elbadawi A, Elgendy IY, Lopez-Fernandez T et al (2024) Cardiovascular Risk in Patients with Hematological Malignancies: A Systematic Review and Meta-Analysis. Am J Cardiol 212:80\u2013102. https:\/\/doi.org\/10.1016\/j.amjcard.2023.11.039","journal-title":"Am J Cardiol"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-026-09178-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:30:20Z","timestamp":1783071020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-026-09178-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":257,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9178"],"URL":"https:\/\/doi.org\/10.1007\/s12016-026-09178-y","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No new studies were performed as part of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"No informed consent was required for this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"M.A.R.: has received research grant support, consultancy fees, speaker fees, and\/or clinical trial fees from Astria, BioCryst, BioMarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, Ionis, KalVista, Novartis, Pharming, Pharvaris, Sanofi-Regeneron, Takeda. D.M.C.: has received consultancy fees from Astria, BioCryst, CSL Behring, Ionis, Intellia, KalVista, Otsuka, Pharvaris, Takeda; speaking fees from CSL Behring, Ionis, Takeda. M.M.: has received research grant support and\/or speaker\/consultancy fees from or is\/was investigator in clinical studies for Astria, BioCryst, CSL Behring, Intellia, KalVista, Novartis, Octapharma, Otsuka, Pharvaris, Takeda. H.F.: has received research grants from CSL Behring, Pharming, Takeda and served as an advisor for these companies and BioCryst, Intellia, KalVista, ONO Pharmaceutical, Pharvaris; has participated in clinical trials\/registries for BioCryst, CSL Behring, KalVista, Pharming, Pharvaris, Takeda. E.A.-P.: has received fees as a speaker and\/or consultant from Astria, BioCryst, BioMarin, CSL Behring, Intellia, KalVista, Otsuka, Pharming, Pharvaris, Takeda; grants from CSL Behring, Takeda. A.B.: has received research funding from Ionis, Astria, and Intellia, and advisory boards with CSL Behring, Ionis, Pharvaris, Intellia, KalVista, Astria, Takeda. J.A.B.: is a consultant and principal investigator for BioCryst, BioMarin, CSL Behring, Intellia, Ionis, KalVista Pharmaceuticals, Pharming, and Takeda\/Shire; and is a consultant for Astria, Cycle Pharmaceuticals, and ONO Pharmaceutical. A.H.S.: Grant\/research support\/funding from the National Institutes of Health and Shire (a Takeda Company); consultancy for Merck; data safety management board for Intellia; scientific advisory board for Rezolute. E.P.: employee of Pharvaris, holds stocks\/stock options in Pharvaris. A.L.: employee of GrayMatters Consulting and consultant to Pharvaris, holds stocks\/stock options in Pharvaris; advisor to Kosa Pharma. P.L.: employee of Pharvaris and holds stock in Pharvaris. D.E.N.: institutional research grants from the British Heart Foundation (CH\/09\/002, RG\/F\/22\/110093, and RE\/24\/130012).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}